Abstracts (Poster and Oral) Presentations

  1. Sayegh N, Swami U, Jo Y, Gebrael G, Haaland B, Gupta S, Plets M, Hussain MH, Quinn DI, Lara Jr. PN, Thompson Jr. IM, Agarwal N. Outcomes of Black (B) versus White (W) patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without orteronel (Ort): Analysis of pt-level data from SWOG-1216 phase 3 trial. Poster Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023.
  2. Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski JK, Ingles S, Triche TJ, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara Jr. PN, Hussain MH, Quinn DI, Dorff TB, Thompson Jr. I, Agarwal N. Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide. Poster Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023.
  3. Thomas VM, Chigarira B, Gebrael G, Sayegh N, Tripathi N, Nussenzveig R, Sahu KK, Li H, Fortuna GG, Tandar C, Goel D, Brundage J, Maughan BL, Swami U, Agarwal N. Differential tumor gene expression profiling of obese and non-obese patients (pts) with prostatic adenocarcinoma (PC). Poster Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023. 
  4. Parikh M, Tangen C, Hussain MH, Gupta S, Jo Y, Harzstark A, Paller CJ, George S, Zibelman MR, Cheng HH, Maughan BL, Zhang J, Pachynski RK, Bryce AH, Lin DW, Quinn DI, Thompson Jr. IM, Dorff TB, Lara Jr. PN, Agarwal N. Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216). Poster Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023. 
  5. Ogobuiro I, Deshmukh S, Wu S, Xiu J, Walker P, Swami U, Oberley MJ, Agarwal N, McKay RR, Nabhan C, Abramowitz M, Pollack A, Dal Pra A, Punnen S, Mahal BA. Characterizing the molecular landscape of early onset and average onset prostate cancer. Poster Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023. 
  6. Azad A, Fizazi K, Matsubara N, Fong PC, Carles J, Shore ND, De Giorgi U, Jones RJ, Karsh LI, Joung JY, Fay AP, Liu G, Yip SM, Zschaebitz S, Hopkins JF, Di Santo N, Lin X, Mata M, Laird D, Agarwal N. Use of circulating tumor DNA (ctDNA) to complement tumor tissue homologous recombination repair (HRR) gene alteration testing in TALAPRO-2, a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Poster Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023. 
  7. Azad A, Fizazi K, Matsubara N, Saad F, De Giorgi U, Joung JY, Fong PC, Jones RJ, Zschaebitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Lin X, DeAnnuntis LL, Di Santo N, Engelsberg A, Agarwal N. Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study. Poster Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023.
  8. Gebrael G, Sayegh N, Tripathi N, Goel D, Brundage J, McFarland TR, Ebrahimi H, Nordblad B, Chigarira B, Thomas VM, Sahu KK, Li H, Chehrazi-Raffle A, Maughan BL, Kohli M, Swami U, Agarwal N. Impact of synchronous (sync) vs metachronous (meta) metastasis at the presentation on survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs). Poster Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023.
  9. Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, Van Loan M, Hussain MH, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc ML, Thompson Jr. IM, Agarwal N. Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel. Poster Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023.
  10. Agarwal N, Azad A, Matsubara N, Saad F, De Giorgi U, Joung JY, Fong PC, Jones RJ, Zschaebitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Cislo P, Chang J, Healy CG, Niyazov A, Fizazi K. Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2). Poster Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023.
  11. Fizazi K, Azad A, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschaebitz S, Oldenburg J, Lin X, Healy CG, Di Santo N, Zohren F, Agarwal N. TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.  Oral Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023.
  12. Loriot Y, Balar AV, Petrylak DP, Rezazadeh A, Grivas P, Flechon A, Jain RK, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos PL, Kyriakopoulos C, Pouessel D, Sternberg CN, Tonelli J, Elboudwarej E, Diehl L, Jürgensmeier JM, Tagawa ST. Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression. Poster Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023.
  13. Talukder R, Bakaloudi DR, Lin GI, Enright T, Leary JB, Makrakis D, Tripathi N, Agarwal N, Jindal T, Koshkin VS, Brown JR, Johnson J, Zakharia Y, Park JJ, Alva AS, Barrera RM, Drakaki A, Barata PC, Khaki AR, Grivas P. Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC). Poster Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023.
  14. McDermott DF, Peer A, Agarwal N, Atkins MB, Cornell J, Perini RF, Grossmann KF, Gurney H. LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC). Poster Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023.
  15. Gebrael G, Saad E, Labaki C, Saliby RM, Sayegh N, Semaan K, Eid M, Takemura K, Ernst MS, Lemelin A, Basappa NS, Wood L, Powles T, Ernst DS, Kapoor A, Xie W, Agarwal N, Heng DY, Choueiri TK.  Impact of smoking status (SS) on the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first line (1L) immuno-oncology (IO)-combination regimens: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Poster Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023.
  16. Hwang J, Zorko N, Elliott A, Lozada JA, Radovich M, Heath EI, Agarwal N, McKay RR, Garje R, Bastos BR, Hoon DS, Nabhan C, Sledge Jr. GW, Antonarakis ES. Pan-cancer associations of B7-H3 (CD276) transcriptional expression across human malignancies. Poster Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023. 
  17. Gandara DR, Agarwal N, Gupta S, Klempner SJ, Andrews MC, Mahipal A, Subbiah V, Eskander RN, Carbone DP, Snider J, Bouzit L, Cho-Phan CD, Price M, Li G, Quintanilha JC, Huang RS, Ross JS, Fabrizio D, Oxnard GR, Graf R. Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types. Oral Presentation. 2023 ASCO Annual Meeting, June 2-6, 2023.
  18. Collier KA, Simon NI, Taylor AK, Hemenway G, Rose TL, Eule CJ, Tripathi N, Rodman C, Kalluri U, Farooq MZ, McKay RR, Jain RK, Sonpavde GP, Sweis RF, Agarwal N, lam ET, Zibelman MR, Emamekhoo H, Apolo AB, Mortazavi A. Multi-center, retrospective study of first-line systemic therapy ± immune checkpoint inhibition for metastatic neuroendocrine carcinoma of the urinary tract. Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 467).
  19. Labaki C, Bakouny Z, Wells JC, Takemura K, Saliby RM, Meza LA, Gebrael G, Porta C, Lee J-L, Basappa NS, Velasco GD, McKay RR, Pal SM, Agarwal N, Donskov F, Braun DA, Henske E, Xie W, Heng DYC, Choueiri TK. Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (IO)-based regimens. Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 654).
  20. Bakaloudi DR, Talukder R, Makrakis D, Agarwal N, Tripathi N, Bamias A, Zakopoulou R, Brown J, Korolewicz J, Fulgenzi CAM, Jindal T, Murgic J, Frobe A, Johnson J, Drakaki A, Rodriquez-Vida A, Rey-Cardenas M, Buznego LAA, Khaki AR, Grivas P. Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients (pts) with advanced urothelial carcinoma (aUC): “Real world” experience. Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 472).
  21. Dizman N, Govindarajan A, Zengin ZB, Meza LA, Tripathi N, Sayegh N, Castro DV, Chan EH, Lee KO, Prajapati SR, Feng MI, Loo V, Pace M, O’brien S, Bailey EB, Barragan-Carrillo R, Chehrazi-Raffle A, Li X, Agarwal N, Pal SM. Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 678).
  22. Petrylak DP, Tagawa ST, Jain RK, Bupathi M, Balar AV, Rezazadeh A, George S, Palmbos PL, Nordquist LT, Davis NB, Ramamurthy C, Sternberg CN, Loriot Y, Agarwal N, Park CH, Tonelli J, Vance M, Zhou H, Grivas P. Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy. Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 520).
  23. Grivas P, Pouessel D, Park CH, Barthelemy P, Bupathi M, Petrylak DP, Agarwal N, Gupta S, Flechon A, Ramamurthy C, Davis NB, Recio-Boiles A, Sternberg CN, Bhatia A, Pichardo C, Sierecki M, Tonelli J, Zhou H, Tagawa ST, Loriot Y. Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy. Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 518).
  24. Tagawa ST, Balar AV, Petrylak DP, Rezazadeh A, Loriot Y, Flechon A, Jain RK, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos PL, Kyriakopoulos C, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zhou H, Grivas P. Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 526).
  25. Talukder R, Bakaloudi DR, Makrakis D, Tripathi N, Agarwal N, Jindal T, Koshkin VS, Johnson J, Zakharia Y, Brown J, Rey-Cardenas M, Castellano D, Alva AS, Zakopoulou R, Korolewicz J, Drakaki A, Barata PC, Grivas P, Khaki AR. Outcomes with immune checkpoint inhibitor (ICI) therapy in patients with FGFR2/3 alterations in advanced urothelial carcinoma (aUC). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 478).
  26. Brown JT, Elliott A, Walker P, Xiu J, Nazha B, Stewart TF, Gulati S, Nandagopal L, Goldman J, Kucuk O, Carthon BC, Barata PC, Hoon DSB, McKay RR, Agarwal N, Nabhan C, Korn WM, Bilen MA. Exploration of immunosuppressive features of the tumor microenvironment within hepatic and non-hepatic tumors of urothelial origin. Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 562).
  27. Chehrazi-Raffle A, Tukachinsky H, Schrock AB, Hwang J, Zengin ZB, Meza LA, Chawla NS, Ebrahimi H, Govindarajan A, Castro DV, Rock A, Tripathi A, Dorff TB, Pal SM, Oxnard GR, Agarwal N, Antonarakis ES. Spectrum and implications of activating BRAF alterations in advanced prostate cancer (aPC). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 220).
  28. McGregor BA, Agarwal N, Suarez C, Tsao K, Kelly WK, Pagliaro LC, Vaishampayan UN, Castellano D, Loriot Y, Xu F, Andrianova L, Sudhagoni R, Choueiri TK, Pal SM. Cabozantinib in combination with atezolizumab in non-clear cell renal cell carcinoma: Extended follow-up results of cohort 10 of the COSMIC-021 study. Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 684).
  29. Smith MR, Matsubara N, McKay RR, Piulats JM, Todenhofer T, Zhang T, Fasnacht N, Sherwood S, Johnston EL, Schaverien C, Lithio A, Nacerddine K, Agarwal N. CYCLONE 3: A phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr TPS289).
  30. Gupta S, Makarov V, Sonpavde GP, Gibb E, Gupta S, Maughan BL, Agarwal N, Mossanen M, Thysagarajan B, Diaz-Montero CM, Bangalore PP, Konety BR. Genomic analysis from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with MIBC undergoing cystectomy. Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 559).
  31. McDermott DF, Peer A, Agarwal N, Atkins MB, Cornell J, Perini RF, Grossmann KF, Gurney H. LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma. Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr TPS747).
  32. Lowentritt BH, Rossi C, Du S, Muser E, Kinkead F, Waters D, Lefebvre P, Pilon D, Agarwal N. Real-world time-to-castration resistance (CR) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide (APA), enzalutamide (ENZ), or abiraterone acetate (ABI) from an oncology database. Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 65).
  33. Agarwal N, Azad A, Carles J, Fay AP, Matsubara N, Heinrich D, Szczylik C, Giorgi UD, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschaebitz S, Lin X, Healy CG, Santo ND, Zohren F, Fizazi K. TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr LBA17).
  34. Agarwal N, Saad F, Azad A, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen H-C, Lanzalone S, Niyazov A, Fizazi K. TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr TPS279).
  35. Tagawa ST, Thomas C, Adra N, Zakharia Y, Philips G, Quinn DI, Agarwal N, Nordquist LT, Wulff-Burchfield EM, Appleman LJ, Posadas EM, Christos PJ, Ballman KV, Nanus DM, Osborne J. Randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr LBA21).
  36. Thomas VM, Sayegh N, Chigarira B, Gebrael G, Jo Y, Tripathi N, Nussenzveig R, Li H, Sahu KK, Tandar C, Goel D, Iyer P, Maughan BL, Swami U, Agarwal N. Tumor transcriptomic profiling of patients (pts) with metastatic castration sensitive prostate cancer (mCSPC) who do versus who do not achieve an optimal PSA response to intensified androgen deprivation therapy (i-ADT). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 234).
  37. Seasor T, Balatico M, Chigarira B, Sahu KK, Kim JT, Matynia AP, Barry M, Albertson DJ, Mahlow J, Swami U, Agarwal N, Sirohi D. Tumor transcriptomic profile in patients (pts) with advanced prostate cancer (PCa) with cribriform and signet ring-like histologies. Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 259).
  38. Kohli M, Lee H, Lin T, Larsen M, Hanson C, Neibling A, Gupta S, Lloyd J, Maughan BL, Johnson SB, Agarwal N, Tward JD, Swami U, ONeil B, Dechet CB, Wang L, Tan A-C, Haaland B. Plasma proteome landscape and impact of the circulatory proteome on clinical outcomes in metastatic prostate cancer. Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 237).
  39. Lloyd J, Nordblad B, Sahu KK, Swami U, Phunrab TK, Batten JA, Maxwell L, Kohli M, Gupta S, Maughan BL, Agarwal N. Investigating documented reasons for withdrawal from clinical trials for patients with advanced prostate cancer (PCa). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 105).
  40. Tward JD, Johnson SB, Kokeny KE, Lloyd S, Cannon DM, Dechet CB, ONeil B, Stephenson R, Boucher KM, Gupta S, Swami U, Maughan BL, Agarwal N. Initial results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-naïve men with oligometastatic prostate cancer to bone. Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 156).
  41. Tripathi N, Li H, Chigarira B, Kumar SA, Kim JT, Sayegh N, Gebrael G, Jo Y, Sahu KK, Thomas VM, Nussenzveig R, Goel D, Tandar C, Rathi N, Swami U, Agarwal N, Maughan BL. Differences in the tumor transcriptomic profile of patients (pts) with advanced prostate cancer (PCa) with and without diabetes mellitus (DM). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 244).
  42. Sayegh N, Tripathi N, Chigarira B, Jo Y, Thomas VM, Nussenzveig R, Sahu KK, Li H, Gebrael G, Tandar C, Goel D, Rathi N, Maughan BL Swami U, Agarwal N. Correlation of tumor gene expression profile and gleason score (GS) in patients (pts) with metastatic prostate cancer. Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 235).
  43. Sahu KK, Jo Y, Chigarira B, Kim JT, Sayegh N, Gebrael G, Tripathi N, Kumar SA, Thomas VM, Li H, Nussenzveig R, Kohli M, Gupta S, Maughan BL, Agarwal N, Swami U. Correlation of age and the tumor transcriptomic profile in patients (pts) with advanced prostate cancer (PCa). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 233).
  44. Li H, Sahu KK, Gebrael G, Chigarira B, Thomas VM, Jo Y, Kumar SA, Nordblad B, Brundage J, Tripathi N, Sayegh N, Swami U, Agarwal N, Maughan BL. Clinical characteristics, tumor genomic and transcriptomic profiles of patients (pts) with metastatic renal cell carcinoma (mRCC) who developed venous thromboembolism (VTE). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 726).
  45. Sahu KK, Tripathi N, Chigarira B, Sayegh N, Thomas VM, Li H, Jo Y, Gebrael G, Iyer Pu, Nussenzveig R, Agarwal N, Maughan BL, Gupta S, Swami U. Characterization of the tumor transcriptomic differences by smoking history in locally advanced or metastatic urothelial carcinoma (UC). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 561).
  46. Thomas VM, Chigarira B, Gebrael G, Sayegh N, Tripathi N, Jo Y, Nussenzveig R, Sahu KK, Li H, Tandar C, Goel D, McFarland TR, Brundage J, Maughan BL, Swami U, Agarwal N. Association of obesity with tumor differential gene expression and gene set enrichment pathways in advanced prostate adenocarcinoma (PCa). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 231).
  47. Li H, Sahu KK, Kumar SA, Thomas VM, Tripathi N, Gebrael G, Sayegh N, Chigarira B, Jo Y, Swami U, Gupta S, Maughan BL, Agarwal N. Access to care and health care quality metrics in urban versus rural patients (pts) with advanced prostate cancer (aPC). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 37).
  48. Sahu KK, Li H, Thomas VM, Benson M, Hawaks J, Brown J, Thorne K, Sherwin K, Cheney J, Boucher KM, Gupta S, Kohli M, Swami U, Agarwal N, Maughan BL. A phase II study of rucaparib monotherapy in nonmetastatic, hormone-sensitive prostate cancer (nmHSPC) with “BCRAness” genotype (ROAR). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr 364).
  49. Swami U, Faust C, Leonhart S, Haaland B, Jones K, Li H, Sahu KK, Thomas VM, Phunrab TK, Batten J, Maxwell L, Lloyd J, Kohli M, Gupta S, Thorne K, Maughan BL, Agarwal N. ENCORE: A phase 2 trial of enfortumab vedotin (EV) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr TPS294).
  50. Swami U, Brown J, Turner A, Haaland B, Jones K, Thomas VM, Sahu KK, Li H, Phunrab TK, Batten J, Maxwell L, Lloyd J, Kohli M, Gupta S, Thorne K, Maughan BL, Agarwal N. AtezoCab: A phase II study of cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with non-measurable disease (NMD). Poster Presentation. 2023 Genitourinary Cancers Symposium, February 15-17, 2023. J Clin Oncol 41, 2023 (suppl 6; abstr TPS295).
  51. Barry M, Mahlow J, Albertson D, Jo Y, Balatico M, Seasor T, Gebrael G, Kumar SA, Sayegh N, Tripathi N, Swami U, Agarwal N, Sirohi D. Are Histological Patterns of Prostate Carcinoma Predictive of Homologous Recombination Deficiency Gene Mutations? Oral Presentation. 2023 USCAP 112th Annual Meeting. March 13, 2023.
  52. Agarwal N, Azad A, Fizazi K, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen HC, Lanzalone S, Niyazov A, Saad F. TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus ENZA in patients with DDR geneâ mutated, metastatic castration-sensitive prostate cancer (mCSPC). 2022 ASCO Annual Meeting, June 3-June 7, 2022.  J Clin Oncol 40, 2022 (suppl 16; abstr TPS221).
  53. Agarwal N, Lucas J, Aguilar-Bonavides C, Thomas S, Gormley M, Chowdhury S, Merseburger AS, Bjartell A, Uemura H, Ozguroglu M, McCarthy S, Brookman-May SD, Lefresne F, Mundle S, Chi KN. Genomic aberrations associated with overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or placebo (PBO) plus androgen deprivation therapy (ADT) in TITAN. 2022 ASCO Annual Meeting, June 3-June 7, 2022.  J Clin Oncol 40, 2022 (suppl 16; abstr 5066).
  54. Sayegh N, Chigarira B, Hernandez EJ, McFarland TR, Li H, Sahu KK, Tripathi N, Kumar SA, Nordblad B, Goel D, Tandar C, Yandell M, Nussenzveig R, Sirohi D, Maughan BL, Swami U, Agarwal N. Transcriptomic profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (DN-mCSPC) versus those with mCSPC that have relapsed from prior localized therapy (PLT-mCSPC). 2022 ASCO Annual Meeting, June 3-June 7, 2022.  J Clin Oncol 40, 2022 (suppl 16; abstr 5080).
  55. Guven DC, Sayegh N, Tripathi N, Erman M, Agarwal N, Swami U. Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis. 2022 ASCO Annual Meeting, June 3-June 7, 2022.  J Clin Oncol 40, 2022 (suppl 16; abstr 5079).
  56. Sayegh N, Peterson B, Tripathi N, Chigarira B, Li H, Sahu KK, Sirohi D, Nussenzveig R, Maughan BL, Agarwal N, Swami U. Clinical and genomic correlates of survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving intensified androgen deprivation therapy (ADT) in a real-world population. Poster Presentation. AACR 2022 Meeting, April 8-13, 2022. Cancer Res 82, 2022 (suppl 12; abstr 5995).
  57. Tripathi N, Jo Y, Sayegh N, Chigarira B, Nordblad B, Thomas VM, Haaland B, Nussenzveig R, Gupta S, Agarwal N, Swami U, Maughan BL. Tumor genomic landscape in patients (pts) with and without liver metastasis in metastatic urothelial carcinoma (mUC). Poster Presentation. AACR 2022 Meeting, April 8-13, 2022. Cancer Res 82, 2022 (suppl 12; abstr 5142).
  58. Li H, Tripathi N, Sayegh N, Cheney J, Nordblad B, Chigarira B, Swami U, Gupta S, Maughan BL, Agarwal N. Access to Care and Health Care Quality Metrics in Urban Versus Rural Patients With Advanced Genitourinary Cancers. NCCN 2022 Annual Conference, March 31-April 2, 2022. JNCCN 20 (3.5).
  59. Chawla NS, Tripathi N, Sayegh N, Govindarajan A, Dizman N, Zengin ZB, Meza LA, Muddasani R, Chehrazi-Raffle A, Salgia S, Malhotra J, Hsu J, Phillip EJ, Bergerot CD, Lyou Y, Swami U, Gupta S, Maughan BL, Agarwal N, Pal SK. Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer. Poster Presentation. 2022 Genitourinary Cancers Symposium, February 17-19, 2022. J Clin Oncol 40, 2022 (suppl 6; abstr 561).
  60. Sayegh N, Tripathi N, McFarland TR, Kessel A, Nussenzveig R, Chigarira B, Li H, Tandar C, Goel D, Nordblad B, Cheney J,  Sahu KK, Maughan BL, Swami U, Agarwal N. Overall survival (OS) after progression on first novel hormonal therapy (NHT) in patients (pts) with metastatic castration-sensitive versus castration-resistant prostate cancer (mCSPC versus mCRPC). Poster Presentation. 2022 Genitourinary Cancers Symposium, February 17-19, 2022. J Clin Oncol 40, 2022 (suppl 6; abstr 121).
  61. Sayegh N, Graf R, Fisher V, Weberpals J, Huang RSP, Lin DI, Gjoerup O, Raskina K, Severson EA, Haberberger J, Ross JS, Alexander BM, Levy MA, Oxnard GR, Agarwal N. Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus taxane chemotherapy benefit in metastatic castration-resistant prostate cancer: A real-world biomarker study. Poster Presentation. 2022 Genitourinary Cancers Symposium, February 17-19, 2022. J Clin Oncol 40, 2022 (suppl 6; abstr 162).
  62. Tripathi N, Jo Y, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi D. Tumor genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation (UCS) compared to pure urothelial carcinoma (UC). Poster Presentation. 2022 Genitourinary Cancers Symposium, February 17-19, 2022. J Clin Oncol 40, 2022 (suppl 6; abstr 553).
  63. Sayegh N, Triptathi N, Chigarira B, Jo Y, McFarland TR, Kessel A, Nussenzveig R, Li H, Tandar C, Goel D, Sahu KK, Haaland B, Maughan BL, Swami U, Agarwal N. Survival outcomes and characterization of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) undergoing intensified androgen deprivation therapy (ADT) who do not achieve an optimal PSA response (PSA ≤0.2 ng/mL). Poster Presentation. 2022 Genitourinary Cancers Symposium, February 17-19, 2022. J Clin Oncol 40, 2022 (suppl 6; abstr 123).
  64. Sayegh N, Jo Y, Tripathi N, McFarland TY, Kessel A, Nussenzveig R, Chigarira B, Li H, Tandar C, Sahu KK, Haaland B, Maughan BL, Swami U, Agarwal N. Genomic characterization of patients (pts) with de-novo high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) compared to those without dn-hv-mCSPC. Poster Presentation. 2022 Genitourinary Cancers Symposium, February 17-19, 2022. J Clin Oncol 40, 2022 (suppl 6; abstr 186).
  65. Tripathi N, Li H, Jo Y, Sayegh N, Tandar C, Nussenzveig R, Haaland B, Cheney J, Goel D, Nordblad B, Gupta S, Maughan BL, Agarwal N, Swami U. Tumor genomic landscape in younger compared to older patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC). Poster Presentation. 2022 Genitourinary Cancers Symposium, February 17-19, 2022. J Clin Oncol 40, 2022 (suppl 6; abstr 373).
  66. Swami U, Chigarira B, Sayegh N, McFarland TR, Tripathi N, Nussenzveig R, Kessel A, Tandar C, Goel D, Cheney J, Nordblad B, Thomas VM, Sirohi D, Maughan BL, Agarwal N. Progression-free survival (PFS) and overall survival (OS) in patients (pts) with de-novo, high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) undergoing intensified androgen deprivation therapy (ADT). Poster Presentation. 2022 Genitourinary Cancers Symposium, February 17-19, 2022. J Clin Oncol 40, 2022 (suppl 6; abstr 133).
  67. Tripathi N, Sayegh N, Jo Y, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Sirohi D, Swami U, Agarwal N, Maughan BL. Tumor genomic landscape in smokers compared to non-smoker patients with locally advanced or metastatic urothelial carcinoma. Poster Presentation. 2022 Genitourinary Cancers Symposium, February 17-19, 2022. J Clin Oncol 40, 2022 (suppl 6; abstr 554).
  68. Shen J, Chowdhury S, Agarwal N, Karsh LI, Oudard S, Gartrell BA, Feyeraben S, Saad F, Pieczonka CM, Chi KN, Brokkman-May SD, Rooney B, Bhaumik A, Londhe A, McCarthy SA, Bevans KB, Mundle SD, Small EJ, Smith MR, Graff JN. Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN. ESMO Congress 2021, September 16-21, 2021. Annals of Oncology 32, 2021 (suppl 5; abstr 618P).
  69. George DJ, Agarwal N, Ramaswamy K, Sandin R, Russell D, Hong A, Yang H, Gao W, Hagan K, Freedland SJ. Real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis. Poster Presentation. ESMO Congress 2021, September 16-21, 2021. Annals of Oncology 32, 2021 (suppl 5; abstr 616P).
  70. Higano CS, Dizdarevic S, Sundar S, Agarwal N, Essler M, Song D, George S, Shore ND, Kurtinecz M, Verholen F, Sandstrom P, Sartor O, George DJ. Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC). Poster Presentation. ESMO Congress 2021, September 16-21, 2021. Annals of Oncology 32, 2021 (suppl 5; abstr 593P).
  71. Loriot Y, Balar AV, Petrylak DP, Rezazadeh A, Grivas P, Flechon A, Jain RK, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos P, Kyriakopoulos C, Pouessel D, Sternber CN, Pan Y, Jurgensmeier JM, Goswami T, Tagawa ST. Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC). Poster Presentation. ESMO Congress 2021, September 16-21, 2021. Annals of Oncology 32, 2021 (suppl 5; abstr 700P).
  72. Chung BH, Huang J, Uemura H, Choi YD, Ye Z, Suzuki H, Kang TW, He D, Joung JY, Brookman-May SD, McCarthy S, Bhaumik A, He J, Mundle SD, Chowdhury S, Agarwal N, Ye D, Chi KN, Uemura H. Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC). Poster Presentation. ESMO Congress 2021, September 16-21, 2021. Annals of Oncology 32, 2021 (suppl 5; abstr 608P).
  73. Agarwal N, McGregor BA, Maughan BL, Dorff T, Kelly W, Fang B, McKay R, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan UN, Goel S, Curran D, Panneerselvam A, Liu L, Choueiri TK, Pal SK. Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): results of expanded cohort 6 of the COSMIC-021 study. Proffered Paper. ESMO Congress 2021, September 16-21, 2021. Annals of Oncology 32, 2021 (suppl 5; abstr LBA24).
  74. Makrakis D, Talukder R, Carril L, de Kouchkovsky I, Park JJ, Bilen MA, McKay RR, Agarwal N, Zakharia Y, Devitt ME, Pinato DJ, Hoimes CJ, Gartrell BA, Tripathi A, Bamias A, Drakaki A, Murgic J, Lorenzo GD, Grivas P, Khaki AR. Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history. 2021 ASCO Annual Meeting, June 4-June 8, 2021, Virtual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr e16526).
  75. Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer RJ, Lee RJ, Jain RK, Davis NB, Appleman LJ, Goodman OB, Stadler WM, Gandhi SG, Geynisman DM, Mellado RIB, Figlin RA, Powles T, Akella LV, Orford KW, Escudier B. CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies. 2021 ASCO Annual Meeting, June 4-June 8, 2021, Virtual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr 4501).
  76. Barata PC, Reisinger R, Bilen MA, Heath EI, Nandagopal L, Swami U, Kessel A, Jaeger E, Wesolowski S, Chipman J, Mack A, Ravindranathan D, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Lilly MB, Sartor AO, Agarwal N. Differences in the tumor genomic landscape between African Americans (AA) and Caucasians (CA) advanced prostate cancer (aPC) patients (pts) by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA). 2021 ASCO Annual Meeting, June 4-June 8, 2021, Virtual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr 5058).
  77. Duarte C, Beuselinck B, Weise N, Dizman N, Collier K, Li H, Martinez N, Elias CR, Rose TL, Brugarolas J, Agarwal N, Mortazavi A, Pal SK, McKay RR, Hu J, Lam ET. Treatment outcomes in renal cell carcinoma patients with metastases to the pancreas and other sites. 2021 ASCO Annual Meeting, June 4-June 8, 2021, Virtual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr 4557).
  78. Swami U, McFarland TR, Haaland B, Kessel A, Nussenzveig R, Sayegh N, Hahn AW, Rathi N, Sirohi D, Esther J, Li Haoran, Kohli M, Maughan BL, Goldkorn A, Agarwal N. Correlation of baseline circulating tumor cells (CTC) and associated genomic profile with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort. 2021 ASCO Annual Meeting, June 4-June 8, 2021, Virtual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr 5077).
  79. Reisinger R, Santos VS, Nussenzveig R, Wesolowski S, Hernandez EJ, Henrie AR, Maughan BL, Swami U, Yandell M, Grivas P, Agarwal N. Genomic predictors of response to PD-1 axis inhibitors in metastatic urothelial cancer (mUC) patients using machine learning analysis of tissue comprehensive genomic profiling (CGP). 2021 ASCO Annual Meeting, June 4-June 8, 2021, Virtual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr 4542).
  80. George DJ, Agarwal N, Rider JR, Li B, Shirali R, Sandin R, Hong A, Russell D, Ramaswamy K, Freedlan SJ. Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings. 2021 ASCO Annual Meeting, June 4-June 8, 2021, Virtual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr 5074).
  81. Freedland SJ, Agarwal N, Ramaswamy K, Sandin R, Russell D, Hong A, Yang H, Gao W, Hagan K, George DJ. Real-world utilization of advanced therapies and racial disparity among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis. 2021 ASCO Annual Meeting, June 4-June 8, 2021, Virtual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr 5073).
  82. Swami U, Hong A, El-Chaar NN, Nimke D, Ramaswamy K, Bell EJ, Sandin R, Agarwal N. Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database. 2021 ASCO Annual Meeting, June 4-June 8, 2021, Virtual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr 5072).
  83. Agarwal N, Chowdhury S, Bjartell A, Chung BH, Gomes AJPS, Given R, Juarez A, Merseburger AS, Ozguroglu M, Uemura H, Ye D, Brookman-May SD, Mundle S, McCarthy SA, Lefresne F, Dibaj S, Bevans KB, Chi KN. Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). 2021 ASCO Annual Meeting, June 4-June 8, 2021, Virtual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr 5068).
  84. Agarwal N, Oudard S, Rodriguez JMMP, Schweizer MT, Flechon A, Gordoa TA, Nacerddine K, Lithio A, Johnston EL, Smith MR. CYCLONE 1: A phase 2 study of abemaciclib in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a novel hormonal agent and taxane-based chemotherapy. 2021 ASCO Annual Meeting, June 4-June 8, 2021, Virtual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr TPS5086).
  85. Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliegy M, Lin X, Niyazov A, Czibere A, Fizazi K. TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC). 2021 ASCO Annual Meeting, June 4-June 8, 2021, Virtual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr TPS5089).
  86. Agarwal N, Tangen C, Hussain MH, Gupta S, Plets M, Lara P, Harzstark A, Twardowski P, Paller CJ, Zylla DM, Zibelman MR, Levine EG, Roth BJ, Goldkorn RA, Vaena DA, Kohli M, Crispino T, Vogelzang NJ, Thompson IM, Quinn DI. SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691). 2021 ASCO Annual Meeting, June 4-June 8, 2021, Virtual Meeting. J Clin Oncol 39, 2021 (suppl 15; abstr 5001).
  87. McFarland TR, Nussenzveig R, Swami U, Sayegh N, Kessel A, Sharma P, Li H, Kohli M, Maughan BL, Pal SK, Agarwal N. Comprehensive genomic profiling of matched primary prostate cancer tissue and cell-free DNA (cfDNA) to assess ontogeny of BRCA1/BRCA2 mutations. Poster presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 166).
  88. Kessel A, McFarland TR, Sayegh N, Morton K, Sirohi D, Kohli M, Swami U, Nussenzveig R, Agarwal N, Maughan BL. Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results. Poster 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 135).
  89. Zengin ZB, Weipert C, Hsu J, Salgia N, Hensel C, Maughan BL, Rathi N, Goel D, Agarwal N, Choueiri TK, Pal SK. Illustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data. Poster 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 347).
  90. Matsubara N, De Bono JS, Olmos D, Procopio G, Kawakami S, Uran Y, van Alphen RJ, Flechon A, Carducci MA, Choi YD, Hotte SJ, Korbenfeld EP, Kramer G, Agarwal N, Dearden S, Gresty C, Kang J, Poehlein CH, Harrington E, Hussain MHA. Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2or ATM: Results from the PROfound study. Poster 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 27).
  91. Chi KN, Chowdhury S, Bjartell A, Chung BH, de Santana Gomes AJP, Given R, Soto AJ, Merseburger AS, Ozguroglu M, Uemura H, Ye D, Triantos S, Mundle S, McCarthy SA, Larsen JS, Sun Weili, Bevans K, Zhang K, Bandyopadhyay N, Agarwal N, For the TITAN Investigators. Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). Poster 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 11).
  92. Sayegh N, Swami U, Barata PC, Lilly MB, Nussenzveig R, Hensel C, Bryce AH, Bilen MA, Heath EI, Nandagopal L, Garje R, Saylor PJ, Babiker HM, Vaena DA, Kohli M, Pal SK, Sartor O, Agarwal N. Real-world prevalence of homologous recombination repair gene (BRCA1/2and ATM) mutations (HRRm) in patients (pts) with advanced prostate cancer (aPC) as detected by comprehensive genomic profiling (CGP) of circulating cell-free DNA (cfDNA). Poster 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 256).
  93. Makrakis D, Castellano D, de Kouchkovsky I, Park JJ, Bilen MA, Agarwal N, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson AA, Gatrell BA, Tripathi A, Bamias A, Rodriguez-Vida A, Liu S, McKay RR, Buznego LAA, Murgic J, Grivas P, Khaki AR. Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC). Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 444).
  94. Agarwal N, Azad A, Carles J, Chowdhury S, McGregor BA, Merseburger AS, Oudard S, Saad F, Soares A, Panneerselvam A, Wang F, Pal SK. A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC). Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr TPS190).
  95. Zengin ZB, Weipert C, Hsu J, Salgia N, Hensel C, Maughan BL, Rathi N, Goel D, Agarwal N, Choueiri TK, Pal SK. llustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data. Poster Presentation. 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 347).
  96. Rathkopf DE, Chi KN, Olmos D, Cheng HH, Agarwal N, Graff JN, Sandhu SK, Hayreh V, Lopez-Gitlitz A, Francis PSJ, Attard G. AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). Poster 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr TPS176).
  97. Reisinger R, Wesolowski S, Swami U, Barata PC, Hernandez EJ, Nussenzveig R, Lemmon G, Peterson B, Hensel C, Bilen MA, Heath EI, Nandagopal L, Saylor PJ, Babiker HM, Kohli M, Pal SK, Lilly MB, Yandell M, Sartor AO, Agarwal N. Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) with BRCA1 versus BRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA). Poster 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 162).
  98. Schmidt AL, Xie W, Gan CL, Wells C, Dudani S, Donskov F, Porta C, Suarez C, Szabados B, Wood L, Morales JMR, Tran B, Bjarnason GA, Yuasa T, Beuselinck B, Hansen AR, Agarwal N, Bakouny Z, Heng DYC, Choueiri TK. The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC). Poster 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 339).
  99. Li H, Swami U, Boucher KM, Gupta S, Hawks J, Sirohi D, Agarwal N, Maughan BL. Combination therapy with avelumab (Ave) and cabozantinib (Cabo) in patients (pts) with newly diagnosed metastatic clear cell renal cell carcinoma (mccRCC). Poster 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 334).
  100. Swami U, McFarland TR, Haaland B, Kessel A, Nussenzveig R, Sayegh N, Hahn AW, Rathi N, Sirohi D, Esther J, Li H, Kohli M, Maughan BL, Goldkorn A, Agarwal N. Association of circulating tumor cells (CTC) with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort. Poster 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 59).
  101. Barata PC, Swami U, Kessel A, Jaeger E, Wesolowski S, Chipman J, Bilen MA, Heath EI, Nandagopal L, Vaena DA, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Agarwal N, Sartor OA. Landscape of circulating tumor DNA (ctDNA) abnormalities in advanced prostate cancer (aPCa): Distinctions in African American (AA) versus Caucasian (Ca) patients. Poster 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 156).
  102. Freeman MM, Jaeger E, Zhu J, Phone A, Nussenzveig R, Caputo S, Ravindranathan D, Layton JL, Nandagopal L, Kessel A, Desai A, Koshkin VS, Basu A, Bilen MA, Swami U, Garcia JA, Agarwal N, Burgess EF, Sartor AO, Barata PC. Multi-institutional evaluation of the clinical outcomes and genomic correlates of African Americans with metastatic castration-sensitive prostate cancer (mCSPC). 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 17).
  103. Graham J, Wells C, Dudani S, Gan CL, Donskov F, Lee JL, Kollmannsberger CK, Pal SK, Beuselinck B, Hansen AR, North SA, Bjarnason GA, Agarwal N, Kanesvaran R, Wood L, Hotte SJ, McKay RR, Choueiri TK, Hen DYC. Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC). 2021 Genitourinary Cancers Symposium, February 11-13, 2021. J Clin Oncol 39, 2021 (suppl 6; abstr 316).
  104. Zengin ZB, Weipert C, Hsu J, Salgia N, Saam J, Choueiri TK, Agarwal N, Pal S. Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing. Proffered Paper. ESMO Virtual Congress 2020, September 19-21, 2020. Annals of Oncology 31, 2020 (suppl 4; abstr 7010).
  105. Pal S, Tsao C, Suarez C, Kelly W, Pagliaro L, Vaishampayan UN, Loriot Y, Srinivas S, McGregor BA, Panneerselvam A, Curran D, Choueiri TK, Agarwal N. Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study. Proffered Paper. ESMO Virtual Congress 2020, September 19-21, 2020. Annals of Oncology 31, 2020 (suppl 4; abstr 7020).
  106. De Bono JS, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Ozguroglu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, Hussain M. Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. Poster Presentation. ESMO Virtual Congress 2020, September 19-21, 2020. Annals of Oncology 31, 2020 (suppl 4; abstr 6100).
  107. Loriot Y, Balar AV, Petrylak DP, Tagawa ST, Rezazadeh A, Flechon A, Jain R, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos PL, Kyriakopoulos CE, Pouessel D, Sternberg CN, Hong Q, Goswami T, Itri LM, Grivas P. TROPHY-U-01 cohort 1 final results: A phase II study of sacituzamab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI). Proffered Paper. ESMO Virtual Congress 2020, September 19-21, 2020. Annals of Oncology 31, 2020 (suppl 4; abstr LBA24).
  108. Grivas P, Sternberg CN, Agarwal N, Petrylak DP, Tagawa ST, Hong Q, Gladden A, Kanwal C, Goswami T, Loriot Y. TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) and pembrolizumab (pempbro) in patients (pts) with progression or recurrence of metastatic urothelial cancer (mUC) after platinum (PLT)-based therapy. Poster Presentation. ESMO Virtual Congress 2020, September 19-21, 2020. Annals of Oncology 31, 2020 (suppl 4; abstr 796TiP).
  109. McGregor BA, Agarwal N, Suarez C, Tsao C, Kelly W, Pagliaro L, Vaishampayan UN, Castellano D, Loriot Y, Werneke S, Curran D, Choueiri TK, Pal S. Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study. Poster Presentation. ESMO Virtual Congress 2020, September 19-21, 2020. Annals of Oncology 31, 2020 (suppl 4; abstr 709P).
  110. Agarwal N, Evans R, Abrams K, Dequen-O’Byrne P, McCrea C, Muston D, Gresty C, Ghate S, Fan L, Hettle R, Hawkins N. Exploring the impact of treatment switching on the interim overall survival (OS) results of the PROfound study. Poster Presentation. ESMO Virtual Congress 2020, September 19-21, 2020. Annals of Oncology 31, 2020 (suppl 4; abstr 622P).
  111. Goldkorn A, Tangen C, Plets M, Morrison G, Cunha A, Xu T, Pinski JK, Ingles SA, Triche T, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara P, Hussain MHA, Quinn DI, Vogelzang NJ, Thompson IM, Agarwal N. Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide. Poster Presentation. 2020 ASCO Virtual Scientific Program, May 29-31, 2020. J Clin Oncol 38, 2020 (suppl; abstr 5506).
  112. Dudani S, Gan CL, Wells C, Bakouny Z, Dizman N, Pal SK, Wood L, Kollmannsberger CK, Szabados B, Powles T, Beuselinck B, Donskov F, Hansen AR, Bjarnason GA, Canil CM, Srinivas S, Agarwal N, Liow ECH, Choueiri TK, Heng DYC. Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes. Poster Presentation. 2020 ASCO Virtual Scientific Program, May 29-31, 2020. J Clin Oncol 38, 2020 (suppl; abstr 5063).
  113. Gan CL, Dudani S, Wells C, Bakouny Z, Dizman N, Pal SK, Szabados B, Wood L, Kollmannsberger CK, Agarwal N, Donskov F, Basappa NS, Bjarnason GA, Parnis F, Porta C, Davis ID, Vaishampayan UN, Kanesvaran R, Choueiri TK, Heng DYC. Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials. Poster Presentation. 2020 ASCO Virtual Scientific Program, May 29-31, 2020. J Clin Oncol 38, 2020 (suppl; abstr 5070).
  114. Denmeade SR, Wang H, Cao H, Fu W, Wang T, Abdallah R, Bolejack V, Agarwal N, Smith DC, Schweizer MT, Stein MN, Assikis VJ, Flaig TW, Szmulewitz RZ, Holzbeirlein J, Paller CJ, Carducci MA, Markowski MC, Eisenberger MA, Antonarakis ES. TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC). Poster Presentation. 2020 ASCO Virtual Scientific Program, May 29-31, 2020. J Clin Oncol 38, 2020 (suppl; abstr 5517).
  115. Petrylak DP, Tagawa ST, Jain RK, Bupathi M, Balar AV, Rezazadeh A, George S, Palmbos PL, Nordquist LT, Davis NB, Vogelzang NJ, Ramamurthy C, Sternberg CN, Loriot Y, Agarwal N, Hong Q, Gladden A, Kanwal C, Goswami T, Grvas P. Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy. Poster 2020 ASCO Virtual Scientific Program, May 29-31, 2020. J Clin Oncol 38, 2020 (suppl; abstr 5027).
  116. Ravi P, Mantia C, Su C, Sorenson K, Rathi N, Bakouny Z, Agarwal N, Costello BA, McKay RR, Narayan V, Alva AS, McGregor BA, Gao X, McDermott DF, Choueiri TK. Use of immune checkpoint inhibitors (ICIs) after prior ICI in metastatic renal cell carcinoma (mRCC): Results from a multicenter collaboration. Poster Presentation. 2020 ASCO Virtual Scientific Program, May 29-31, 2020. J Clin Oncol 38, 2020 (suppl; abstr 5077).
  117. Palmbos PL, Tomlins SA, Daignault S, Agarwal N, Twardowski P, Morgans AK, Kelly WK, Arora V, Antonarakis ES, Siddiqui J, Robinson D, Knidsen KE, Chinnaiyan A, Hussain MHA. Clinical outcomes and markers of treatment response in a randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-intact metastatic hormone-sensitive prostate cancer (mHSPC). Poster Presentation. 2020 ASCO Virtual Scientific Program, May 29-31, 2020. J Clin Oncol 38, 2020 (suppl; abstr 5573).
  118. Lara P, Mayerson E, Gertz E, Tangen C, Goldkorn A, Loan MV, Hussain MHA, Gupta S, Zhang J, Twardowski P, Quinn DI, Vogelzang NJ, Thompson IM, Agarwal N. Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel. Poster Presentation. 2020 ASCO Virtual Scientific Program, May 29-31, 2020. J Clin Oncol 38, 2020 (suppl; abstr 5523).
  119. Chi KN, Saad F, Chowdury S, Graff JN, Agarwal N, Oudard S, Li G, Lopez-Gitlitz A, Larsen JS, McCarthy SA, Mundle S, Smith MR, Small EJ. Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies. Poster Presentation. 2020 ASCO Virtual Scientific Program, May 29-31, 2020. J Clin Oncol 38, 2020 (suppl; abstr 5541).
  120. Feng FY, Thomas S, Aguilar-Bonavides C, Gormley M, Agarwal N, Attard G, Wyatt AW, Davicioni E, Ricci DS, Lopez-Gitlitz A, Larsen JS, Chowdhury S, Chi KN. Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN. Poster Presentation. 2020 ASCO Virtual Scientific Program, May 29-31, 2020. J Clin Oncol 38, 2020 (suppl; abstr 5535).
  121. Swami U, Sinnott JA, Haaland B, Maughan BL, Rathi N, McFarland TR, Kohli M, Nussenzveig R, Pal SK, Agarwal N. Overall survival (OS) with docetaxel (D) vs novel hormonal therapy (NHT) with abiraterone (A) or enzalutamide (E) after a prior NHT in patients (Pts) with metastatic prostate cancer (mPC): Results from a real-world dataset. Poster 2020 ASCO Virtual Scientific Program, May 29-31, 2020. J Clin Oncol 38, 2020 (suppl; abstr 5537).
  122. Smith MR, Agarwal N, Todenhofer T, Trepiakas R, Lee JL, Lithio A, Chapman S, Nacerddine K, Sweeney C. CYCLONE 2: A phase II, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer. Poster Presentation. 2020 ASCO Virtual Scientific Program, May 29-31, 2020. J Clin Oncol 38, 2020 (suppl; abstr TPS5591).
  123. Pal SK, Agarwal N, Loriot Y, Rodriguez CS, Singh P, Vaishampayan UN, Mcilvaine E, Curran D, Castellano D, Necchi A. Cabozantinib in combination with atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy: Results from cohort 2 of the COSMIC-021 study. Poster Presentation. 2020 ASCO Virtual Scientific Program, May 29-31, 2020. J Clin Oncol 38, 2020 (suppl; abstr 5013).
  124. Swami U, Haaland B, Maughan BL, Nussenzveig R, Esther J, Kessel A, Pal SK, Grivas P, Agarwal N. Comparative effectiveness of second-line (2L) single-agent atezolizumab (A), nivolumab (N), and pembrolizumab (P) in patients (Pts) with locally advanced or metastatic urothelial cancer (aUC) who progressed on platinum-based systemic chemotherapy (plat-chemo): Results from a real-world dataset. Poster Presentation. 2020 ASCO Virtual Scientific Program, May 29-31, 2020. J Clin Oncol 38, 2020 (suppl; abstr 5032).
  125. Agarwal N, Shore ND, Dunshee C, Karsh LI, Azad A, Fay AP, Carles J, Paccagnella ML, Santo ND, Elmeliegy M, Lin X, Quek RGW, Czibere A, Fizazi K. TALAPRO-2: a placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC). Poster Presentation. 2020 ASCO Virtual Scientific Program, May 29-31, 2020. J Clin Oncol 38, 2020 (suppl; abstr TPS5598).
  126. Agarwal N, Loriot Y, McGregor BA, Dreicer R, Dorff TB, Maughan BL, Kelly WK, Pagliaro LC, Srinivas S, Squillante CM, Vasihampayan UN, Wang EW, Curran D, Choueiri TK, Pal SK. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study. Poster 2020 ASCO Virtual Scientific Program, May 29-31, 2020.
    J Clin Oncol 38, 2020 (suppl; abstr 5564).
  127. Agarwal N, Chowdhury S, Bjartell A, Chung BH, de Santana Gomes AJP, Given RW, Soto AJ, Merseburger AS, Ozguroglu M, Uemura H, Ye D, Londhe A, Lopez-Gitlitz A, McCarthy SA, Mundle S, Chi KN. Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-senstitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane). Oral Presentation. 2020 Genitourinary Cancers Symposium, February 13, San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 82).
  128. Bakouny Z, Xie W, Dudani S, Wells C, Gan CL, Donskov F, Shapiro J, Davis ID, Parnis F, Ravi P, Steinharter JA, Agarwal N, Alva AS, Wood L, Kapoor A, Morales JMR, Kollmannsberger CK, Beuselinck B, Heng DYC, Choueiri TK. Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis. Poster 2020 Genitourinary Cancers Symposium, February 15, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 608).
  129. Gupta S, Sonpavde G, Weight CJ, McGregor BA, Gupta G, Maughan BL, Wei XX, Gibb E, Thyagarajan B, Einstein DJ, Dechet CB, Lowrance WT, Murugan PJ, Kilbridge KL, Agarwal N, Davicioni E, Eckstein M, Mossanen M, Preston MA, Konety BR. Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. Oral 2020 Genitourinary Cancers Symposium, February 14, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 439).
  130. Rathi N, Stenehjem DD, Agarwal N, Hahn AW, Sirohi D, Sharma P, Koh MY, Maughan BL. Association of serum iron and response to immune checkpoint inhibitors (ICIs) in metastatic clear cell renal cell carcinoma (mccRCC). Poster 2020 Genitourinary Cancers Symposium, February 15, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 723).
  131. Maughan BL, Nussenzveig R, Swami U, Gupta S, Agarwal N. Prospective trial of nivolumab (Nivo) plus radium-223 (RA) in metastatic castration-resistant prostate cancer (mCRPC) evaluating circulating tumor DNA (ctDNA) levels as a biomarker of response. Poster 2020 Genitourinary Cancers Symposium, February 13, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr TPS267).
  132. Agarwal N, Shore ND, Dunshee C, Karsh LI, Azad A, Fay AP, Carles J, Sullivan B, Santo ND, Elmeliegy M, Lin X, Quek RGW, Czibere A, Fizazi K. TALAPRO-2: A placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC). Poster 2020 Genitourinary Cancers Symposium, February 13, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr TPS264).
  133. Agarwal N, Loriot Y, McGregor BA, Dreicer R, Dorff TB, Maughan BL, Kelly WK, Pagliaro LC, Srinivas S, Squillante CM, Vaishampayan UN, Liu Y, Curran D, Choueiri TK, Pal SK. Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study. Poster 2020 Genitourinary Cancers Symposium, February 13, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 139).
  134. Hahn AW, Kessel A, McFarland TR, Swami U, Nussenzveig R, Esther J, Goel D, Sirohi D, Maughan BL, Agarwal N. Response to systemic therapy and survival otucomes in de-novo (D1) metastatic castration-sensitive prostate cancer (mCSPC) versus mCSPC with prior local therapy (D0). Poster 2020 Genitourinary Cancers Symposium, February 13, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 46).
  135. Maughan BL, Sanchez A, O’Neil BB, Lowrance WT, Dechet CB, Albertson DJ, Sirohi D, Gupta S, Swami U, Agarwal N. A phase Ib/II trial of perioperative intratumoral MVA-BN-brachyury (MVA) plus systemic PROSTVAC and atezolizumab (Atezo) for intermediate-risk and high-risk localized prostate cancer (AtezoVax). Poster 2020 Genitourinary Cancers Symposium, February 13, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr TPS382).
  136. Lin E, Wesolowski S, Nussenzveig R, McFarland TR, Swami U, Maughan BL, Yandell M, Agarwal N. Identification of genomic alterations in signaling pathways associated with poor survival in newly diagnosed metastatic prostate cancer (mCSPC) using artificial intelligence (AI). Poster 2020 Genitourinary Cancers Symposium, February 13, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 169).
  137. Esther J, Swami U, Chipman J, McFarland TR, Hahn AW, Sirohi D, Sharma P, Nussenzveig R, Agarwal N, Maughan BL. Genomic alterations in visceral versus nonvisceral “metastatic” site tumor tissue in metastatic prosate cancer (mPC). Poster 2020 Genitourinary Cancers Symposium, February 13, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 167).
  138. Kessel A, Tran S, Rivers Z, Hahn AW, Nussenzveig R, Rathi N, Maughan BL, Sirohi D, Stenehjem DD, Agarwal N. Identification of genomic aberrations associated with overall survival in metstatic clear cell renal cell carcinoma (mccRCC). Poster 2020 Genitourinary Cancers Symposium, February 15, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 745).
  139. Wesolowski S, Nussenzveig R, Santos VS, Esther J, Goel D, Swami U, Gupta S, Maughan BL, Yandell M, Grivas P, Agarwal N. Genomic correlates of response to PD-1 axis inhibitors (IO) in metastatic urothelial cancer (mUC) using explainable artificial intelligence (AI). Poster 2020 Genitourinary Cancers Symposium, February 14, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 570).
  140. Maughan BL, Hahn AW, Nussenzveig R, Hoffman J, Morton K, Gupta S, Batten JA, Thorley J, Hawks J, Santos VS, Nachaegari G, Wang X, Boucher KM, Haaland B, Agarwal N. Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints. 2020 Genitourinary Cancers Symposium, February 13, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 125).
  141. Gupta S, Maughan BL, Dechet CB, Lowrance WT, O’Neil B, Kokeny KE, Lloyd S, Tward JD, Boucher KM, Agarwal N. NEXT: A phase II, open-label study of nivolumab adjuvant to chemoradiation in patients (pts) with localized muscle invasive bladder cancer. 2020 Genitourinary Cancers Symposium, February 14, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr TPS605).
  142. Wong RL, Duong MT, Tangen C, Agarwal N, Cheng HH, Vogelzang NJ, Hussain MHA, Thompson IM, Quinn DI, Yu EY. Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of androgen deprivation (AD) +/- cixutumab, in new metastatic hormone-sensitive prostate cancer (mHSPC). 2020 Genitourinary Cancers Symposium, February 13, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 106).
  143. Hutson TE, Michaelson MD, Kuzel TM, Agarwal N, Molina AM, Hsieh JJ, Vaishampayan UN, Xie S, Bapat U, Jain RK, Fishman MN. A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC). 2020 Genitourinary Cancers Symposium, February 15, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 685).
  144. Andrews E, Curran C, Grivas P, Diamantopoulos N, Drakaki A, Jain RK, Tandon A, Agarwal N, Tripathi A, Santos VS, Hussain SA, Sonpavde G. Outcomes of advanced plasmacytoid urothelial carcinoma receiving systemic therapy. 2020 Genitourinary Cancers Symposium, February 14, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 580).
  145. Tannir NM, Agarwal N, Pal SK, Cho DC, Formiga M, Guo J, George DJ, Tagliaferri MA, Singel SM, O’Keeffe BA, Hannah AL, Balbas M, Penkov K. PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator’s choice) in patients with previously untreated advanced renal cell carcinoma (RCC). 2020 Genitourinary Cancers Symposium, February 15, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr TPS763).
  146. Swami U, Velho PI, Nussenzveig R, Santos VS, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, Agarwal N. Impact of somatic SPOP (Speckle-Type POZ protein) mutation (mtSPOP) on response to systemic therapy and survival ourcome in men with de novo metastatic castration-sensitive prosate cancer (d-mCSPC). 2020 Genitourinary Cancers Symposium, February 13, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 329).
  147. Duarte C, Chanza NM, Collier K, Dizman N, Rathi N, McKay RR, Panian J, Narayan V, Carneiro BA, Mega AE, Hu J, Meguid C, Agarwal N, Pal SK, Mortazavi A, Harshman LC, Lam ET. Outcomes of patients with pancreatic-only oligometastatic renal cell carcinoma (RCC). 2020 Genitourinary Cancers Symposium, February 15, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 681).
  148. Ozguroglu M, Chowdhury S, Bjartell A, Uemura H, Chung BH, Agarwal N, Merseburger AS, Soto AJ, Lopez-Gitlitz A, Bhaumik A, Larsen JS, McCarthy SA, Chi KN. Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low-and high-risk disease. 2020 Genitourinary Cancers Symposium, February 13, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 87).
  149. Stukalin I, Dudani S, Wells C, Gan CL, Pal SK, Dizman N, Powles T, Donskov F, Wood L, Bakouny Z, Kollmannsberger CK, Basappa NS, Hansen AR, de Velasco G, Beuselinck B, Canil CM, Vaishampayan UN, Agarwal N, Choueiri TK, Heng DYC. Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). 2020 Genitourinary Cancers Symposium, February 15, 2020. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 6; abstr 684).
  150. Tagawa S, Balar A, Petrylak D, Grivas P, Agarwal N, Sternberg C, Hong Q, Gladden A, Kanwal C, Siemon-Hryczyk P, Goswami T, Itri L, Lorit Y. Initial Results From TROPHY-U-01: A Phase 2 Open-Label Study of Sacituzumab Govitecan in Patients (Pts) With Metastatic Urothelial Cancer (mUC) After Failure of Platinum-Based Regimens (PLT) or Immunotherapy. Poster Presentation. ESMO 2019 Congress. September 27- October 1. 2019. Barcelona, Spain.
  151. Antonarakis E, Isaacsson Velho P, Agarwal N, Sacristan Santos V, Maughan B, Pili R, Adra N, Sternberg C, Vlachostergios P, Tagawa S, Bryce A, Mcnatty A, Reichert Z, Dreicer R, Sartor O, Lotan T, Hussain M. CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors. Poster Presentation. ESMO 2019 Congress. September 27- October 1. 2019. Barcelona, Spain.
  152. Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Gomes A, Chung B.H., Özgüroğlu M. Juárez Soto A, Merseburger A, Uemura H, Ye D, Given R, Miladinovic B, Dearden L, Deprince K, Naini V, Lopez-Gitlitz A, Chi K. Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castrationsensitive prostate cancer (mCSPC). Poster Presentation. ESMO 2019 Congress. September 27- October 1. 2019. Barcelona, Spain.
  153. Choueiri T, Kocsis J, Pachynski R, Poprach A, Deshazo M, Zakharia Y, Lara P, Pal S, Geczi L, Ho T, Mangel L, Redman B, Ryan C, Olencki T, Simpson B, Adams B, Robertson L, Darif M, Theuer C, Agarwal N. Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC). Poster Presentation. ESMO 2019 Congress. September 27- October 1. 2019. Barcelona, Spain.
  154. Chi K, Thomas S, Agarwal N, Feng F, Attard G, Wyatt AW, Gormley M, Ricci DS,  Lopez-Gitlitz A, Deprince K, Larsen J, Chen W, Miladinovic B, Naini V, Chowdhury S. Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN Last update. Poster Presentation. ESMO 2019 Congress. September 27- October 1. 2019. Barcelona, Spain.
  155. Sacristan Santos V, Esther J, Maughan B, Wesolowski S, Lin E, Hahn A, Sirohi D, Rathi N, Swami U, Nussenzveig R, Agarwal N. Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS). Poster Presentation. ESMO 2019 Congress. September 27- October 1. 2019. Barcelona, Spain.
  156. Mcgregor B, Agarwal N, Gordon M, George S, Quinn D, Rogalski M, Keler T, Hawthorne T, Choueiri T. Safety and efficacy of CDX-014, an antibody-drug conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced renal cell carcinoma. Poster Presentation. ESMO 2019 Congress. September 27- October 1. 2019. Barcelona, Spain.
  157. Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi K, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman C, De Bono J. PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. Poster Presentation. ESMO 2019 Congress. September 27- October 1. 2019. Barcelona, Spain.
  158. Necchi A, Pal SK, Ross JS, Madison R, Agarwal N, Sonpavde G, Joshi M, Yin M, Miller VA, Grivas P, Chung J, Ali SM. Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development. 2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, IL. J Clin Oncol 37, 2019 (suppl; abstr 4581).
  159. Tripathi A, Lin E, Nussenzveig R, Yandell M, Pal SK, Agarwal N. NT5E expression and the immune landscape of prostate cancer (PC): An analysis from The Cancer Genome Atlas database. 2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, IL. J Clin Oncol 37, 2019 (suppl; abstr e16591).
  160. Hahn AW, Lin E, Esther J, Anderson N, Rathi N, Yandell M, Maughan BL, Agarwal N. Genomic landscape of metastatic hormone senstitive prostate cancer (mHSPC) vs. metastatic castration-refractory prostate cancer (mCRPC) by circulating tumor DNA (ctDNA). 2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, IL. J Clin Oncol 37, 2019 (suppl; abstr 5043).
  161. Tannir NM, Agarwal N, Pal SK, Formiga MN, Guo J, Tagliaferri MA, Hannah AL, Zhang JY, O’Keeffe BA, Cho DC. A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator’s choice) in patients with previously untreated advanced renal cell carcinoma. Poster Presentation. 2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, IL. J Clin Oncol 37, 2019 (suppl; abstr TPS4595).
  162. Rathkopf DE, Saleh MN, Tsai FYC, Bilen MA, Rosen LS, Gottardis M, Infante JR, Adams BJ, Liu L, Theuer CP, Freddo JL, Agarwal N. An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer. Poster Presentation. 2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, IL. J Clin Oncol 37, 2019 (suppl; abstr e16542).
  163. Grivas P, Puligandla M, Cole S, Courtney KD, Dreicer R, Gartrell BA, Cetnar JP, Dall’era M, Galsky MD, Jain RK, Maughan BL, Agarwal N, Koshkin VS, Hahn NM, Carducci MA. PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer (BC). Poster Presentation. 2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, IL. J Clin Oncol 37, 2019 (suppl; abstr TPS4594).
  164. Lin E, Nussenzveig R, Hahn AW, Yandell M, Harshman LC, Agarwal N, Tripathi A. Immune correlates of CD73 expression in patients with urothelial carcinoma (UC). Poster Presentation. 2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, IL. J Clin Oncol 37, 2019 (suppl; abstr 4548).
  165. Agarwal N, Shore ND, Dunshee C, Karsh LI, Sullivan B, Santo ND, Elmeliegy M, Lin X, Czibere AG, Fizazi K. Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC). Poster Presentation. 2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, IL. J Clin Oncol 37, 2019 (suppl; abstr 5076).
  166. Agarwal N, Shore ND, Dunshee C, Karsh LI, Sullivan B, Santo ND, Elmeliegy M, Lin X, Quek RGW, Czibere AG, Fizazi K. TALAPRO-2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC). Poster Presentation. 2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, IL. J Clin Oncol 37, 2019 (suppl; abstr TPS5092).
  167. Tagawa ST, Petrylak DP, Grivas P, Agarwal N, Sternberg CN, Hernandez C, Siemon-Hryczyk P, Goswami T, Loriot Y. TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy. Poster Presentation. 2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, IL. J Clin Oncol 37, 2019 (suppl; abstr TPS3153).
  168. Lin E, Hahn AW, Sonpavde G, Lilly MB, Nussenzveig R, Ledet E, Pal SK, Grivas P, Rich TA, Raymond VM, Sartor O, Yandell M, Agarwal N. Profiling of genomic alterations in MAPK/ERK signaling in a large cohort of metastatic prostate cancer (mPC) patients. Poster Presentation. 2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, IL. J Clin Oncol 37, 2019 (suppl; abstr 5032).
  169. Chi KN, Agarwal N, Bjartell A, Chung BH, Gomes AJPS, Given RW, Soto AJ, Merseburger AS, Ozguroglu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy SA, Chowdhury S. First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). Poster Presentation. 2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, IL. J Clin Oncol 37, 2019 (suppl; abstr 5006).
  170. Appleman LJ, Puligandla M, Pal SK, Harris W, Agarwal N, Costello BA, Ryan CW, Pins M, Kolesar J, Vaena DA, Parikh RA, Hashmi M, Dutcher JP, DiPaola RS, Haas NB, Carducci MA. Randomized, double-blind phase III study of pazopanib versus placebo in patients with mtastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810). Poster Presentation. 2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, IL. J Clin Oncol 37, 2019 (suppl; abstr 4502).
  171. Bandini M, Pederzoli Filippo, Madison R, Briganti A, Plimack ER, Ross JS, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Rosenberg JE, Bellmunt J, Galsky MD, Gallina A, Salonia A, Montorsi F, Ali SM, Chung J, Necchi A. Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets. Poster Presentation. 2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, IL. J Clin Oncol 37, 2019 (suppl; abstr 4535).
  172. Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, Giorgi UD, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Sternberg CN, Bellmunt J, Baniel J, Niegisch G. Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival. Poster Presentation. 2019 ASCO Annual Meeting, May 31-June 4, 2019, Chicago, IL. J Clin Oncol 37, 2019 (suppl; abstr e16017).
  173. Tannir NM, Agarwal N, Dawson NA, Motzer RJ, Jacobs CM, Choueiri TK, Hrom JS, Geynisman DM, Davis NB, Figlin RA, O’Keeffe MK, Parikh JR, Vaena DA, Liu PY, O’Keeffe B, Tran X, Escudier B. CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma. Poster Presentation. 2019 Genitourinary Cancers Symposium, February 16, 2019, San Francisco, CA. J Clin Oncol 37, 2019 (suppl 7S; abstr TPS682).
  174. Pal SK, Vaishampayan UN, Castellano DE, Necchi A, Van Herpen CML, Ramsingh G, Loriot Y, Agarwal N. Phase 1b (COSMIC-021) trial of cabozantinib (C) in urothelial carcinoma (UC) or C in combination with atezolizumab (A) in patients (pts) with UC, castrate resistant prostate cancer (CRPC) or renal cell carcinoma (RCC). Poster Presentation. 2019 Genitourinary Cancers Symposium, February 16, 2019, San Francisco, CA. J Clin Oncol 37, 2019 (suppl 7S; abstr TPS683).
  175. Agarwal N, Pal SK, Lauer RC, Chatta GS, Goel S, Singh P, Sundararajan S, Heaton C, Peterson C, Benaim E, Tagawa ST. Results of a phase II study to evaluate the safety and efficacy of RX-0201 in combination with everolimus in subjects with metastatic renal cell carcinoma (mRCC). Poster Presentation. 2019 Genitourinary Cancers Symposium, February 16, 2019, San Francisco, CA. J Clin Oncol 37, 2019 (suppl 7S; abstr 646).
  176. Hahn AW, Drake CG, Denmeade SR, Zakharia Y, Maughan BL, Kennedy EP, Link CJ, Vahanian NN, Hammers HJ, Agarwal N. Efficacy of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients (pts) with refractory metastatic renal cell carcinoma (mRCC). Poster Presentation. 2019 Genitourinary Cancers Symposium, February 16, 2019, San Francisco, CA. J Clin Oncol 37, 2019 (suppl 7S; abstr 590).
  177. Hahn AW, Haaland B, Rathi N, Dizman N, Maughan BL, Pal SK, Agarwal N. Receipt of systemic therapy in older versus younger patients (pts) with metastatic renal cell carcinoma (mRCC). Poster Presentation. 2019 Genitourinary Cancers Symposium, February 16, 2019, San Francisco, CA. J Clin Oncol 37, 2019 (suppl 7S; abstr 580).
  178. Tagawa ST, Petrylak DP, Grivas P, Agarwal N, Sternberg CN, Siemon-Hryczyk P, Goswam T, Loriot Y. TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy. Poster Presentation. 2019 Genitourinary Cancers Symposium, February 15, 2019, San Francisco, CA. J Clin Oncol 37, 2019 (suppl 7S; abstr TPS495).
  179. Ko L, Lilly MB, Hahn AW, Nussenzveig R, Moses MM, Ledet E, Manogue C, Cotogno P, Lewis BE, Layton JL, Agarwal N, Sartor AO, Barata PC. Genomic changes of AR in ctDNA prior to enzalutamide in men with mCRPC after abiraterone acetate. Poster Presentation. 2019 Genitourinary Cancers Symposium, February 15, 2019, San Francisco, CA. J Clin Oncol 37, 2019 (suppl 7S; abstr 320).
  180. Griswold CR, Bailey EB, Mauser JC, Boucher KM, Agarwal N, Gupta S, Maughan BL. Risk factors for venous thromboembolism (VTE) during chemotherapy in patients with germ cell tumors (GCT). Poster Presentation. 2019 Genitourinary Cancers Symposium, February 15, 2019, San Francisco, CA. J Clin Oncol 37, 2019 (suppl 7S; abstr 520).
  181. Agarwal N, Shore ND, Dunshee C, Karsh LI, Sullivan B, Santo ND, Elmeliegy M, Casey M, Quek RGW, Czibere A, Fizazi K. TALAPRO-2: A  two-part, placebo-controlled phase III study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC). Poster Presentation. 2019 Genitourinary Cancers Symposium, February 14, 2019, San Francisco, CA. J Clin Oncol 37, 2019 (suppl 7S; abstr TPS337).
  182. Teerlink C, Hahn AW, Esther J, Rathi N, Farnham JM, Agarwal N, Cannon-Albright L. A Genome-wide association study of metastatic prostate cancer. Poster Presentation. 2019 Genitourinary Cancers Symposium, February 14, 2019, San Francisco, CA. J Clin Oncol 37, 2019 (suppl 7S; abstr 160).
  183. Lin E, Hahn AW, Sonpavde G, Lilly MB, Nussenzveig R, Ledet E, Pal SK, Grivas P, Rich TA, Raymond VM, Sartor AO, Yandell M, Agarwal N. Discovery of targetable mutational signatures in advanced prostate cancer (aPC) using machine learning and next-generation sequencing (NGS) of circulating tumor DNA (ctDNA). Poster Presentation. 2019 Genitourinary Cancers Symposium, February 14, 2019, San Francisco, CA. J Clin Oncol 37, 2019 (suppl 7S; abstr 226).
  184. Tward JD, O’Neil B, Stephenson RA, Agarwal N, Farr T, Petragallo R, Lowrance WT. Survival outcomes for adjuvant or salvage radiation in men with pN+M0 prostate cancer. Poster Presentation. 2019 Genitourinary Cancers Symposium, February 14, 2019, San Francisco, CA. J Clin Oncol 37, 2019 (suppl 7S; abstr 276).
  185. Pal SK, Szeto C, Reddy SK, Nussenzveig R, Lam RY, Scholz MC, Agarwal N. Concomitant characterization of androgen receptor (AC) and immune checkpoints (ICs) in cell-free (cf) DNA and RNA from patients with metastatic castration resistant prosate cancer (mCRPC). Poster Presentation. 2019 Genitourinary Cancers Symposium, February 14, 2019, San Francisco, CA. J Clin Oncol 37, 2019 (suppl 7S; abstr 286).
  186. Sonpavde GP, Pond GR, Nagy RJ, Lalani AA, Faltas B, Agarwal N, Gupta SV, Drakaki A, Vaishampayan UN, Wang J, Barata PC, Gopalakrishan D, Naik G, McGregor BA, Lanman RB, Grivas P. Circulating tumor dna alterations in advanced urothelial carcinoma and association with clinical outcomes. Poster Presentation. 19th Annual Meeting of the Society of Urologic Oncology (SUO). November 28-30. 2018. Phoenix, Arizona.
  187. Agarwal N, Vaishampayan U, Green M, di Nucci F, Chang PY, Scheffold C, Pal S. Phase 1b study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced renal cell carcinoma (RCC). Poster Presentation. ESMO 2018 Congress. October 19-23. 2018. Munich, Germany.
  188. Hahn AW, Kapron AL, Boyle J, Kohlmann W, Poole A, Gill DM, Greenberg S, Hale P, Teerlink C, Maughan BL, Cannon-Albright L, Agarwal N, Cooney KA. Prevalence of clinically actionable germline pathogenic variants (PVs) in advanced prostate cancer (aPC). Poster Presentation. ESMO 2018 Congress. October 19-23. 2018. Munich, Germany.
  189. Maughan BL, Hahn A, Hoffman J, Morton K, Gupta S, Batten J, Thorley J, Hawks J, Nachaegari G, Nussenzveig R, Boucher K, Agarwal N. Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) vs. EZ alone in metastatic castration refractory prostate cancer (Mcrpc). Poster Presentation. ESMO 2018 Congress. October 19-23. 2018. Munich, Germany.
  190. Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Twardowski P, Quinn DI, Vogelzang NJ, Thompson I, Agarwal N. Bone metabolism biomarkers (BMB) in hormone sensitive prosotate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) 1/-orteronel. Poster Presentation. ESMO 2018 Congress. October 19-23. 2018. Munich, Germany.
  191. Ali SM, Chung J, Dewal N, Gay LM, He Y, Sokol ES, Millis SZ, Killan JK, Schrock AB, Pal SK, Miller VA, Ross JS, Agarwal N. Prospecticve comprehensive genomic profiling (CGP) of 3,343 primary and metastatic site prostate tumors. Poster Presentation. ESMO 2018 Congress. October 19-23. 2018. Munich, Germany.
  192. Bandidni M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Theodore C, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A. Relapse-free survival (RFS) of clinical T2-4N0 urothelial bladder carcinoma (UBC) after radical cystectomy (RC), with or without perioperative chemotherapy (POC): Endpoints for clinical trial design. 2018 ASCO Annual Meeting, June 1-5, 2018. Chicago, IL.
  193. Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Kantoff PW. Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer. 2018 ASCO Annual Meeting, June 1-5, 2018. Chicago, IL.
  194. Fishman MN, Clark JI, Alva AS, Curti BD, Agarwal N, Hauke RJ, Mahoney KM, Moon H, Treisman J, Tykodi S, Daniels GA, Morse M, Wong MKK, Kaufman H, Gregory NC, Dutcher JP. Overall survivial (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM. 2018 ASCO Annual Meeting, June 1-5, 2018. Chicago, IL.
  195. Chanza NM, Bosse D, Bilen MA, Geynisman DM, Balakrishnan A, Jain RK, Bowman IA, Zakharia Y, Narayan V, Beuselinck B, Agarwal N, McKay RR, Hsu J, Shah S, Tripathi A, Lam ET, Rose RL, Carneiro BA, Vogelzang NJ, Harshman LC. Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): A retrospective multicenter analysis.  2018 ASCO Annual Meeting, June 1-5, 2018. Chicago, IL.
  196. Bardia A, Rich TA, Raymond VM, Fairclough SR, Sartor AO, Lilly MB, Nezami M, Patel SP, Carneiro BA, Fan AC, Brufsky A, Parker BA, Bridges BB, Agarwal N, Maughan BL, Lanman RB, Cristofanilli M. Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer. 2018 ASCO Annual Meeting, June 1-5, 2018. Chicago, IL.
  197. Tannir NM, Motzer RJ, Agarwal N, Liu PY, Whiting SH, O’Keeffe B, Tran X, Fiji GP, Escudier B. CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma. 2018 ASCO Annual Meeting, June 1-5, 2018. Chicago, IL.
  198. Hahn AW, Gill DM, Hale P, Poole A, Nussenzveig R, Wilson S, Farnham JM, Stephenson RA, Maughan BL, Cannon-Albright L, Agarwal N. Germline variant alleles in rs12422149 of SLCO2B1 and response to abiteraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC). 2018 ASCO Annual Meeting, June 1-5, 2018. Chicago, IL.
  199. Hahn AW, Ledet E, Stenehjem DD, Nussenzveig R, Braithwaite M, Maughan BL, Lilly MB, Sartor O, Agarwal N. Association of genomic alterations (GAs) in circulating tumor DNA (ctDNA) with preogression on abiraterone acetate (AA) or enzalutamide (enza) in advanced prostate cancer.  Poster Presentation. 2018 ASCO Annual Meeting, June 1-5, 2018. Chicago, IL.
  200. Agarwal N, Azad A, Fay A, Carles J, Shore ND, Nordquist LT, Karsh LI, Dunshee C, Nandakumar SP, Sullivan B, Czibere A, Wang F, Fizazi K. Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair deficiencies. Poster Presentation. 2018 ASCO Annual Meeting, June 1-5, 2018. Chicago, IL.
  201. Stenehjem DD, Hahn AW, Nussenzveig R, Carroll E, Gill DM, Bailey EB, Batten JA, Maughan BL, Agarwal N. Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in advanced prostate cancer (aPC) over treatment and time. Poster Presentation. 2018 ASCO Annual Meeting, June 1-5, 2018. Chicago, IL.
  202. Grivas P, Pond GR, Nagy RJ, Barata PC, Mendiratta P, Gopalakrishnan D, Drakaki A, Gupta S, Agarwal N, Wang J, Faltas B, Vaishampayan UN, Naik G, McGregor BA, Pal SK, Kiedrowski LA, Lanman RB, Sonpavde G. Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC). Poster Presentation. 2018 ASCO Annual Meeting, June 1-5, 2018. Chicago, IL.
  203. Bosse D, Xie W, Ged Y, Hahn AW, Bergerot PG, Ho TH, McKay RR, Rose L, de Velasco G, Tannir NM, Tamboli P, Appleman LJ, Rathmell K, Hakimi AA, Pal SK, Agarwal N, Heng DYC, Signoretti S, Voss MH, Choueiri TK. Alterations in key clear cell renal carcinoma (RCC) genes to refine patient prognosis. Poster Presentation. 2018 ASCO Annual Meeting, June 1-5, 2018. Chicago, IL.
  204. Wei XX, McKay RR, Gray KP, Stadler WM, McDermott DF, McGregor BA, Agarwal N, Kyriakopoulos C, Carneiro BA, Rose TL, Zakharia Y, Braun DA, Livak KJ, Wu CJ, Allen EMV, Signoretti S, Lang JM, Hodi FS, Choueiri TK, Harshman LC. Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study. Poster Presentation. 2018 ASCO Annual Meeting, June 1-5, 2018. Chicago, IL.
  205. Maughan BL, Hoffman JM, Morton K, Koppula B, Batten JA, Thorley J, Hawks J, Boucher K, Agarwal N. Safety data from a phase II randomized trial of radium-223 dichloride (Ra-223) plus enzalutamide (Enza) vs. Enza alone in men with metastatic castration refractory prostate cancer (mCRPC). Poster Presentation. 2018 ASCO Annual Meeting, June 1-5, 2018. Chicago, IL.
  206. Twardowski P, Wu X, Plets M, Tangen C, Plimack E, Agarwal N, Vogelzang NJ, Wang J, Tao S, Thomson I, Lara P. Exome Sequencing of Tumor Samples from S1107 “Randomized Phase II Evaluation of Tivantinib and Tivantinib in Combination with Erlotinib in Patients with Papillary Renal Cell Carcinoma (pRCC). Poster Presentation. ESMO 2017 Congress. Sept 8-12. 2017. Madrid, Spain.
  207. Donskov F, Xie W, Wells J, Fraccon A, Pasini F, Porta C, Stukalin I, Lee J, Bamias A, Yuasa T, Davis ID, Pezaro C, Kanesvaran R, Bjarnason GA, Sim H, Agarwal N, Kollmannsberger CK, Canil CM, Choueiri TK, Heng DY. Synchronous vs metachronous metastatic disease: Impact of time to metastasis on outcome in metastatic renal cell carcinoma patients treated with targeted therapy. Poster Presentation. ESMO 2017 Congress. Sept 8-12. 2017. Madrid, Spain.
  208. Pal SK, Agarwal N, Choueiri TK, Stephens PJ, Ross JS, Miller VA, Ali SM, Chung J, Grivas P. Comparison of tumor mutational burden (TMB) in relevant molecular subsets of metastatic urothelial cancer (MUC). Poster Presentation. ESMO 2017 Congress. Sept 8-12. 2017. Madrid, Spain.
  209. Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Wong Y, Pal SK, De Giorgi U, Ladoire S, Agarwal N, YU EY, Niegisch G, Sternberg CN, Srinivas A, Vaishampayan U, Necchi A, Rosenberg JE, Powles T, Bellmunt J, Galsky MD. Impact of cisplatin-based therapy on long-term survival in advanced urinary tract cancer (aUTC). A Retrospective International Study of Invasive/advanced cancer of the urothelium (RISC). Poster Presentaion. ESMO 2017 Congress. Sept 8-12. 2017. Madrid, Spain.
  210. Agarwal N, Pal SK, Sonpavde G, Kiedrowski LA, Nagy RJ, Banks K, Lanman R, Grivas P. Comparison of circulating tumor DNA (ctDNA) profile in metastatic urothelial carcinoma (mUC) derived from the upper tract (UT) and lower tract (LT). Poster Presentation. ESMO 2017 Congress. Sept 8-12. 2017. Madrid, Spain.
  211. Necchi A, Pond GR, Pal SK, Agarwal N, Bowles D, Plimack E, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Golshayan A, Sridhar S, Berthoid D, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD. Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: focus on a special patient population. Poster Presentation. ESMO 2017 Congress. Sept 8-12. 2017. Madrid, Spain.
  212. Michaelson MD, Gupta S, Agarwal N, Szmulewitz RZ, Powles T, Pili R, Bruce JY, Vaishampayan UN, Larkin JMG, Rosbrook B, Lechuga M, Valota O, Tarazi JC, Shepard DR. Axitinib plus crizotinib in patients with advanced solid tumors and metastatic renal cell carcinoma (mRCC): Preliminary phase 1b results. Poster Presentation. 2017 ASCO Annual Meeting, June 1-5, 2017. Chicago, IL.
  213. De Bono JS, Hussain M, Thiery-Vuillemin A, Mateo J, Sartor AO, Chi KN, Fizazi K, Twardowski P, Agarwal N, Sandhu SK, Olmos D, Shore ND, Saad F, Liu S, Goessl CD, Burgents J. PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration. Poster Presentation. 2017 ASCO Annual Meeting, June 1-5, 2017. Chicago, IL.
  214. Vogelzang NJ, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N. Real-world outcomes among patients who initiated pazopanib or Sunitinib as first targeted therapy for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare date. Poster Presentation. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 20-24, 2017, Boston, MA.
  215. Twardowski P, Wong J, Pal SK, Frankel PH, Franklin K, Junqueira M, Prajapati MR, Harwood D, Agarwal N. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-t alone in patients with metastatic castrate resistant prostate cancer.  Poster Presentation. 2017 Genitourinary Cancers Symposium, February 16, 2017, Orlando, Florida.
  216. Hahn, AW, Gill, DM, Streeter J, Bailey EB, Carroll E, Aryal L, Batten JA, Gupta S, Agarwal N, Maughan BL. Intra-individual genomic diversity between circulating tumor cell-free DNA (cfDNA) and tumor tissue testing in metastatic renal cell carcinoma (mRCC). Poster Presentation. 2017 Genitourinary Cancers Symposium, February 16, 2017, Orlando, Florida.
  217. Hammers HJ, Drake CG, Zakharia Y, Kennedy EP, Vahanian NN, Link CJ, Agarwal N. A phase 1 study of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients with metastatic renal cell cancer. Poster Presentation. 2017 Genitourinary Cancers Symposium. February 16, 2017, Orlando, Florida.  
  218. Vogelzang NJ, Pal SK, Ghate S, Li N, Swallow E, Peeples M, Zichlin M, Meiselback M, Perez JR, Agarwal N. Real-world economic outcomes among patients (pts) who initiated sunitinib or pazopanib as first targeted therapy (TT) for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data. Poster Presentation. 2017 Genitourinary Cancers Symposium, February 16, 2017, Orlando, Florida.
  219. Poole A, Gill DM, Hahn AW, Johnson E, Carroll E, Batten JA, Gupta S, Boucher KM, Maughan BL, Agarwal N. Incidence and characterization of antiandrogen withdrawal syndrome (AAWS) after enzalutamide (ENZA) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). Poster Presentation. 2017 Genitourinary Cancers Symposium, February 16, 2017, Orlando, Florida.
  220. Hahn AW, Gill DM, Poole A, Farnham JM, Cannon-Albright LA, Agarwal N. Independent validation of effect of HSD3B1 genotype on response to androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer (HSPC). Poster Presentation. 2017 Genitourinary Cancers Symposium, February 16, 2017, Orlando, Florida.
  221. Carroll E, Gill DM, Poole A, Hahn AW, Bailey EB, Streeter J, Batten JA, Gupta S, Agarwal N, Maughan BL. Genomic diversity between primary tumor tissue and tumor circulating cell-free DNA (cfDNA) in patients (pts) with metastatic prostate cancer. Poster Presentation. 2017 Genitourinary Cancers Symposium, February 16, 2017, Orlando, Florida.
  222. Gill DM, Gaston D, Hahn AW, Bailey EB, Buckley TH, Johnson E, Batten JA, Alex A, Boucher KM, Stenehjem DD, Agarwal N. Efficacy of eplerenone (Epe) in the management of mineralocorticoid excess (MCE) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (AA) without prednisone (P). Poster Presentation. 2017 Genitourinary Cancers Symposium, February 16, 2017, Orlando, Florida.
  223. Gill DM, Agarwal N, Hahn AW, Johnson E, Poole A, Carroll E, Boucher KM, Salama ME, Agarwal AM. Impact of circulating tumor cell (CTC) nucleus size on outcomes with abiraterone acetate (AA) therapy in men with metastatic castration-resistant prostate cancer (mCRPC). Poster Presentation. 2017 Genitourinary Cancers Symposium, February 16, 2017, Orlando, Florida.
  224. Gupta S, Albertson DJ, Parnell T, Dalley B, Shea JO, Weston A, Butterfield A, Pappas LM, Schiffman JD, Sharma S, Agarwal N. Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC). Poster Presentation. 2017 Genitourinary Cancers Symposium, February 16, 2017, Orlando, Florida.
  225. Gupta S, Albertson DJ, Gaston D, Heilbrun ME, Agarwal N, Liu T, Miller VA, Ross JS, Millis SZ, Ali SM. Comprehensive genomic sequencing of urothelial tumors to identify rare driver genomic alterations in SMARCB1 in a subset of patients. Poster Presentation. 2017 Genitourinary Cancers Symposium, February 16, 2017, Orlando, Florida.
  226. Gill DM, Stenehjem DD, Cheng HH, Kessler ER, Hahn AW, Gupta S, Alex A, Patel SB, Chittoria N, Twardowski P, Vaishampayan UN, Agarwal N. Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC). Poster Presentation. 2017 Genitourinary Cancers Symposium, February 16, 2017, Orlando, Florida.
  227. Palmbos PL, Tomlins SA, Agarwal N, Twardowski P, Morgans AK, Kelly WK, Arora V, Antonarakis ES, Siddiqui J, Daignault S, Knudsen KE, Feng FYC, Hussain M. Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC). Poster Presentation. 2017 Genitourinary Cancers Symposium, February 16, 2017, Orlando, Florida.
  228. Sonpavde G, Nagy RJ, Sartor AO, Pond GR, Gourdin TS, Nandagopal L, Ledet EM, Agarwal N, Carroll E, Naik G, Wang J, Bilen MA, Grivas P, Lanman RB, Talasaz A, Lilly MB. Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy. Poster Presentation. 2017 Genitourinary Cancers Symposium, February 16, 2017, Orlando, Florida.
  229. Pal SK, Sonpavde G, Agarwal N, Vogelzang NJ, Srinivas S, Haas NB, Signoretti S, Lanman RB, Banks K, Choueiri TK. Evolution of circulating tumor DNA (ctDNA) profile from first-line (1L) to second-line (2L) therapy in metastatic renal cell carcinoma (mRCC). Poster Presentation. 2017 Genitourinary Cancers Symposium, February 16, 2017, Orlando, Florida.
  230. Stukalin I, Wells C, Fraccon AP, Pasini F, Porta C, Moreira RB, Srinivas S, Bowman IA, Brugarolas J, Lee JL, Donskov F, Beuselinck B, Bamias A, Rini BI, Sim HW, Agarwal N, Rha SY, Kanesvaran R, Choueriri TK, Heng DYC. Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Poster Presentation. 2017 Genitourinary Cancers Symposium, February 16, 2017, Orlando, Florida.
  231. Bamias A, Tzannis K, Liontos M, Harshman L, Crabb SJ, Wong YN, Pal SK, Powles TB, Bellmunt J, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Sternberg CN, Alva A, Srinivas S, Rosenberg J. Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database. Poster Presentation. ESMO 2016 Congress, October 7-11, 2016, Copenhagen, Denmark.
  232. Bamias A, Tzannis K, Liontos M, Crabb SJ, Harshman L, De Giorgi U, Bellmunt J, Wong YN, Pal SK, Ladoire S, Sternberg CN, Powles TB, Yu EY, Niegisch G, Necchi A, Vaishampayan U, Agarwal N, Rosenberg. Adherence to cisplatin-based regimens prescription in “fit” patients fulfilling platinum eligibility criteria. Impact on outcomes: a retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis. Poster Presentation. ESMO 2016 Congress, October 7-11, 2016, Copenhagen, Denmark.
  233. Choueiri T, Agarwal N, Ho T, Pal SK, Seon B, Jivani M, Adams B, Shazer R, Theuer C. TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC). Poster Presentation. ESMO 2016 Congress, October 7-11, 2016, Copenhagen, Denmark.
  234. Agarwal N, Heemers H, Farnham JM, Patel SB, Gill DM, Gupta S, Teerlink C, Stephenson RA, Alex A, Cannon-Albright LA. Association of single nucleotide polymorphisms (SNPs) in TPD52 gene with response to treatment with enzalutamide (ENZA) in men with metastatic castration refractory prostate cancer (mCRPC). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 5066)
  235. Nagy RJ, Agarwal N, Gupta S, Pal SK, Grivas P, Vaishampayan UN, Wang J, Naik G, Lanman RB, Talasaz A, Sonpavde G. Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma of the bladder. Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 4528)
  236. Sonpavde G, Nagy RJ, Agarwal N, Gourdin TS, Naik G, Eshaghian S, Wang J, Armstrong AJ, Vaishampayan UN, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB. Profiling of circulating tumor (ct)-DNA for potentially actionable targets in prostate cancer (PCa). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 5035)
  237. Pond GR, Sonpavde G, Plets M, Tangen CM, Hussain M, Lara P, Goldkorn A, Garzotto M, Mack PC, Higano CS, Vogelzang NJ, Thompson IM, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk P, Quinn DI. Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421. Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 5079)
  238. Alex A, Stenehjem DD, Twardowski P, Cheng HH, Gill DM, Buckley H, Patel SB, Kessler ER, Chittoria N, Poudel A, Vaishampayan UN, Agarwal N. Impact of prior definitive therapy on survival outcomes in men with new hormone-sensitive metastatic prostate cancer (mHSPC). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 5083)
  239. Sonpavde G, Nelson RA, Trinh Q, Agarwal N, Nix J, Kardos S, Bellmunt J, Choueiri TK, Pal SK. Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 4524)
  240. Wells JC, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Knox JJ, Beuselinck B, Rha SY, Agarwal N, Brugarolas J, Lee JL, Pal SK, Srinivas S, Ernst DS, Vaishampayan UN, Wood L, Simpson R, Velasco G, Choueiri TK, Heng DYC. Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC). Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 4554)
  241. Agarwal N, Tagawa ST, Chatta GS, Pal SK, Goel S, Mazhari R, Heaton C, Benaim E. Results from a phase 1b/2 study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma. Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 2559)
  242. Goldkorn A, Plets M, Agarwal N, Hussain M, Lara P, Vaena DA, MacVicar GR, Crispino T, Harzstark AL, Twardowski P, Tangen CM, Hugen CM, Xu T, Xu Y, Pinski JK, Ingles SA, Higano CS, Vogelzang NJ, Thompson IM, Quinn DI. Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC). Poster Discussion Session. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 11516)
  243. Bergerot PG, Sonpavde G, Nelson RA, Agarwal N, Costa CN, Hsu J, Choueiri TK, Pal SK. Trends in neoadjuvant chemotherapy (NAC) use for muscle-invasive bladder cancer (MIBC): An updated report using the National Cancer Database (NCDB).  Poster Presentation. 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 4540)
  244. Tagawa S, Chatta GS, Pal SK, Goel S, Mazhari R, Heaton C, Benaim E, Agarwal N. Phase Ib/II Study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma – Phase Ib results. Poster Presentation. 2016 AACR Annual Meeting, April 16-20, 2016, New Orleans, LA. (abstr CT114)
  245. Au TH, Bailey EB, Patel SB, Tantravahi SK, Agarwal N, Stenehjem DD. Effect of concomitant proton pump inhibitor (PPI) on effectiveness of tyrosine kinase inhibitor (TKI) in patients with metastatic renal cell carcinoma (mRCC). Poster Presentation. 2016 Genitourinary Cancers Symposium, January 6-9, 2016, San Francisco, CA. J Clin Oncol 34, 2016 (suppl 2S; abstr 608)
  246. Parker SJ, Pond GR, Sonpavde G, Alex A, Heilbrun ME, Agarwal N. Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC). Poster Presentation. 2016 Genitourinary Cancers Symposium, January 6-9, 2016, San Francisco, CA. J Clin Oncol 34, 2016 (suppl 2S; abstr 191)
  247. Bergerot PG, Nelson RA, Ye DW, Grivas P, Singh P, Agarwal N, Choueiri TK, Pal SK. Risk of secondary urinary bladder cancer (UBC) in patients receiving radiotherapy for rectal cancer, prostate cancer, and gynecologic magnancies. Poster Presentation. 2016 Genitourinary Cancers Symposium, January 6-9, 2016, San Francisco, CA. J Clin Oncol 34, 2016 (suppl 2S; abstr 363)
  248. Au TH, Bailey EB, Patel SB, Tantravahi SK, Agarwal N, Stenehjem DD. Risk of hepatotoxicity with concurrent statin and tyrosine kinase inhibitor (TKI) or mTOR inhibitor (mTORi) in patients with metastatic renal cell carcinoma (mRCC). Poster Presentation. 2016 Genitourinary Cancers Symposium, January 6-9, 2016, San Francisco, CA. J Clin Oncol 34, 2016 (suppl 2S; abstr 610)
  249. Sonpavde G, Nagy RJ, Apolo AB, Agarwal N, Pal SK, Grivas P, Vaishampayan UN, Lanman RB, Talasaz A. Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma. Oral Presentation. 2016 Genitourinary Cancers Symposium, January 6-9, 2016, San Francisco, CA. J Clin Oncol 34, 2016 (suppl 2S; abstr 358)
  250. Alex A, Stenehjem DD, Twardowski P, Cheng HH, Buckley TH, Gill D, Patel SB, Vaishampayan UN, Agarwal N. Impact of prior definitive therapy on survival outcomes in men with new hormone sensitive metastatic prostate cancer (mHSPC). Poster Presentation. 2016 Genitourinary Cancers Symposium, January 6-9, 2016, San Francisco, CA. J Clin Oncol 34, 2016 (suppl 2S; abstr 269)
  251. Gill D, Alex A, Farnham JM, Buckley TH, Patel SB, Agarwal AM, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA, Agarwal N. Association of single nucleotide polymorphism in four genes and response to androgen deprivation therapy (ADT) in men with advanced hormone sensitive prostate cancer (aHSPC). Poster Presentation. 2016 Genitourinary Cancers Symposium, January 6-9, 2016, San Francisco, CA. J Clin Oncol 34, 2016 (suppl 2S; abstr 224)
  252. Buckley TH, Alex A, Farnham JM, Gill D, Patel SB, Teerlink C, Albright FS, Stephenson, RA, Cannon-Albright LA, Agarwal N. Assiciation of single nucleotide polymorphisms (SNPs) in SULT1E1 with response to treatment with abiraterone acetate (AA) in men with metastatic castration refractory prostate cancer (mCRPC). Poster Presentation. 2016 Genitourinary Cancers Symposium, January 6-9, 2016, San Francisco, CA. J Clin Oncol 34, 2016 (suppl 2S; abstr 222)
  253. Li H, Kroeger N, deVelasco G, Donskov F, Sim HW, Wells C, Stukalin I, Agarwal N, Parekh HD, Rini BI, Knox JJ, Pantuck AJ, Choueiri TK, Heng DYC. The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy. Poster Presentation. 2016 Genitourinary Cancers Symposium, January 6-9, 2016, San Francisco, CA. J Clin Oncol 34, 2016 (suppl 2S; abstr 552)
  254. Escudier BJ, Motzer RJ, Powles T, Tannir NM, Davis ID, Donskov F, Grunwald V, Heng DYC, Hutson T, Melichar B, Nosov D, Rini BI, Salman P, Sternberg CN, Szczylik C, Wolter P, Arroyo AM, Mangeshkar M, Agarwal N, Choueiri TK. Subgroup analysis of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). Poster Presentation. 2016 Genitourinary Cancers Symposium, January 6-9, 2016, San Francisco, CA. J Clin Oncol 34, 2016 (suppl 2S; abstr 499)
  255. Ramos, J, Wong YN, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, Hussain SA, Baniel J, Golshayan AR, Powles T, Rosenberg JE, Giorgi UD, Vaishampayan UN, Agarwal N, Pal SK, Harshman LC, Necchi A, Recine F, Galsky MD, Yu EY, RISC Investigators. Venous thromboembolism (VTE) risk in patients with localized urinary tract tumors (UTT). Poster Presentation. 2016 Genitourinary Cancers Symposium, January 6-9, 2016, San Francisco, CA. J Clin Oncol 34, 2016 (suppl 2S; abstr 422)
  256. Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood L, Kollmannsberger CK, Rha SY, North SA, Kanesvaran R, Rini BI, Broom RJ, Yamamoto H, Kaymakcalan MD, Heng DYC, Choueiri TK. DiscontinuingVEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC). Oral Presentation. 2016 Genitourinary Cancers Symposium, January 6-9, 2016, San Francisco, CA. J Clin Oncol 34, 2016 (suppl 2S; abstr 503)
  257. Davis ID, Xie W, Pezaro CJ, Donskov F, Wells C, Agarwal N, Srinivas Sandhya, Yuasa T, Beuselinck B, Wood L, Ernst DS, Kanesvaran R, Knox JJ, Pantuck AJ, Saleem S, Alva AS, Rini BI, Lee JL, Choueiri TK, Heng DYC. Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy. Poster Presentation. 2016 Genitourinary Cancers Symposium, January 6-9, 2016, San Francisco, CA. J Clin Oncol 34, 2016 (suppl 2S; abstr 534)
  258. Schwartz G, Adkins D, Heist R, Werner T, Abbott M, Barber S, Slusarz K, Agarwal N, Neuteboom S, Faltaos D, Chen I, Christensen J, Chao R, Bauer T. A first-in-human phase 1/1b study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors. Poster Presentation. 18th ECCO-40th ESMO European Cancer Congress, September 25-29, 2015, Vienna, Austria.
  259. Carducci M, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang NJ, Delva R, Harza M, Thanos A, James N, Werbrouck P, Bögemann M, Hutson T, Milecki P, Nederman T, Sternberg C. A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC). Presidential Presentation. Abstract 4BA. 18th ECCO-40th ESMO European Cancer Congress, September 25-29, 2015, Vienna, Austria.
  260. Pal S, Vuong W, Zhang W, Deng J, Liu X, Ruel N, Pinnamaneni M, Twardowski P, Lau C, Yu H, Figlin R, Agarwal N, Jones J. Clinical and translational assessment of VEGFR1 as a mediator of the pre-metastatic niche: Neoadjuvant axitinib in high-risk localized prostate cancer. Poster Presentation. 18th ECCO-40th ESMO European Cancer Congress, September 25-29, 2015, Vienna, Austria.
  261. Harshman L, Werner L, Wong YN, Yu E, Alva E, Crabb S, Powles T, Rosenberg J, Baniel J, Vaishampayan U, Berthold D, Ladoire S, Hussain S, Milowsky M, Agarwal N, Necchi A, Pal S, Recine F, Bellmunt J, Galsky M. Patterns and potential benefit of adjuvant chemotherapy for residual muscle invasive disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). Poster Presentation. 18th ECCO-40th ESMO European Cancer Congress, September 25-29, 2015, Vienna, Austria.
  262. Agarwal N, Buckley TH, Farnham JM, Patel SB, Agarwal AM, Tantravahi SK, Teerlink C, Albright FS,  Stephenson RA, Alex A, Cannon-Albright LA. Association of single nucleotide polymorphisms (SNPs) in STS and SULT2B1 and response to androgen deprivation therapy (ADT) in men with advanced hormone sensitive prostate cancer (aHSPC). Poster Presentation. AACR Precision Medicine: Integrating Clinical Genomics and Cancer Therapy, June 13-16, 2015, Salt Lake City, Utah.
  263. Fay AP, Kwiatkowski DJ, Gray KP, Thorner A, Rini BI, Agarwal N, Ho TH, Song J, Barrios PM, Albiges L, Mendel Van Allen E, Krajewski KM, Porta C, Pal SK, Bellmunt J, McDermott DF, Heng DYC, Signoretti S, Choueiri TK. Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort. Poster Presentation. ASCO Annual Meeting May 29-June1, 2015, Chicago, IL. J Clin Oncol 33:5s, 2015 (suppl; abstr 4519)
  264. Agarwal N, Alex A, Farnham JM, Patel SB, Tantravahi SK, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA. Association of single nucleotide polymorphisms (SNPs) in ESR1 and PRMT8 and reponse to treatment with abiraterone acetate (AA) in men with metastatic castration refractory prostate cancer (mCRPC). Poster Presentation. ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL. J Clin Oncol 33:5s, 2015 (suppl; abstr 5048)
  265. Li H, Choueiri TK, Welss C, Agarwal N, Donskov F, Lee J, Broom RJ, Yuasa T, Rini BI, Pal SK, Wood L, Ernst DS, Kollmannsberger CK, Vaishampayan UN, Rha SY, Bjarnason GA, Knox JJ, Saleem S, Beuselinck B, Heng DYC. Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC). Poster Presentation. ASCO Annual Meeting May 29-June1, 2015, Chicago, IL. J Clin Oncol 33:5s, 2015 (suppl; abstr 4558)
  266. Palmbos PL, Feng FY, Tomlins SA, Kelly WK, Morgans AK, Taplin M, Agarwal N, Antonarakis ES, Twardowski P, Jacobson J, Davenport MS, Daignault S, Knudsen KE, Hussain M. A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer. Poster Presentation. 2015 ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL. J Clin Oncol 33:5s, 2015 (suppl; abstr TPS5074)
  267. Harshman LC, Werner L, Wong Y, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Recine F, Bellmunt J, Galsky MD, RISC Investigators. Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). Poster Presentation. 2015 ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL. J Clin Oncol 33:5s, 2015 (suppl; abstr 4524)
  268. Twardowski P, Plets M, Plimack ER, Agarwal N, Tangen CM, Vogelzang NJ, Thompson IM, Lara P. SWOG 1107: Parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC). Poster Presentation. 2015 ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL. J Clin Oncol 33:5s, 2015 (suppl; abstr 4523)
  269. Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Straubhar AM, Agarwal AM, Van Atta J, Grossmann KF, Samlowski WE, Redman BG, Agarwal N, Alva AS.  Extension of overall survival (OS) beyond objective responses (OR) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2). Poster Presentation.  2015 ASCO Annual Meeting May 29-June 1, 2015, Chicago, IL. J Clin Oncol 33:5s, 2015(suppl; abstr 4565)
  270. Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman JM. MDFDG- and FLT-PET for early measurement of response to 37.5 mg per day of sunitinib in metastatic renal cell carcinoma. Poster Presentation (#1213). 2015 Society of Nuclear Medicine and Molecular Imaging, June 2015. Baltimore, MD.
  271. Penson D, Armstrong A, Concepcion R, Agarwal N, Wang F, Wu K, Amelsberg A, Phung D, Higano C. “A Multicenter Phase 2 Study of Enzalutamide (ENZA) versus Bicalutamide (BIC) in Men with Nonmetastatic (M0) or Metastatic (M1) Castration-Resistant Prostate Cancer (CRPC): the STRIVE Trial”. Plenary Oral Presentation. 2015 American Urological Association’s (AUA) Annual Meeting, May 15-19, 2015.  New Orleans, LA.
  272. Albright FS, Agarwal N, Lowrance WT, Stephenson RA, Cannon-Albright LA. “Risk for death from prostate cancer predicted from complete family history of lethal prostate cancer”.  Poster Presentation.  2015 American Association for Cancer Research (AACR) Annual Meeting, April 18-22, 2015. Philadelphia, PA.
  273. Cannon-Albright LA, Teerlink CC, Stephenson RA, Agarwal N.  “Significant evidence for linkage for lethal prostate cancer on chromosome arm 4q in Utah high-risk pedigrees”.  Poster Presentation.  2015 American Association for Cancer Research (AACR) Annual Meeting, April 18-22, 2015, Philadelphia, PA.
  274. Flaig TW, Tangen CM, Hussain M, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IM. Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL. J Clin Oncol 33, 2015 (suppl 7; abstr 152)
  275. Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Lorenzo G, Vaishampayan UN, North SA, Agarwal N, Hussain SA, Eigl BJ. Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL. J Clin Oncol 33, 2015 (suppl 7; abstr 335)
  276. Ramos J, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Sternberg CN, Alva AS, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY. Impact of chemotherapy (CTX) on venous thromboembolism (VTE) and prognostic implications in patients with metastatic urinary tract tumors (UTT). Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL. J Clin Oncol 33, 2015 (suppl 7; abstr 318).
  277. Agarwal N, Buckley TH, Farnham JM, Patel SB, Alex A, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA. Germ line predictors of response to androgen deprivation therapy in men with advanced prostate cancer. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL. J Clin Oncol 33, 2015 (suppl 7; abstr 162).
  278. Buckley TH, Patel SB, Tantravahi SK, Batten JA, Stenehjem DD, Alex A, Agarwal N. Correlation of baseline serum testosterone (T) and prostate-specific antigen (PSA) at 7 months (7 mo PSA) in patients (pts) with new hormone sensitive metastatic prostate cancer (mHSPC) treated with continous androgen deprivation therapy (cADT). Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL. J Clin Oncol 33, 2015 (suppl 7; abstr 231).
  279. Tanravahi SK, Patel SB, Ravulapati S, Batten JA, Merriman J, Stenehjem D, Agarwal N. Long-term response in metastatic renal cell carcinoma patients receiving first-line therapy with VEGF TKIs. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL. J Clin Oncol 33, 2015 (suppl 7; abstr 436).
  280. Albright FS, Agarwal N, Lowrance WT, Stephenson RA, Alex A, Cannon-Albright LA. Risk for death from prostate cancer predicted from complete family history of lethal prostate cancer (LPC). Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL. J Clin Oncol 33, 2015 (suppl 7; abstr 175).
  281. Cannon-Albright LA, Teerlink C, Alex A, Albright FS, Stephenson RA, Agarwal N. A genome-wide linkage study of lethal prostate cancer predisposition gene in a set of high-risk pedigrees. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL. J Clin Oncol 33, 2015 (suppl 7; abstr 159).
  282. Patel SB, Agarwal N, Hsu J, Tantravahi SK, Gill D, Vuong W, Batten JA, Stenehjem DD, Pal SK. Everolimus (EVE) versus temsirolimus (TEM) after first-line treatment with VEGF TKI in patients with metastatic renal cell carcinoma. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL. J Clin Oncol 33, 2015 (suppl 7; abstr 460).
  283. Patel SB, Tantravahi SK, Gill D, Poole A, Merriman J, Batten JA, Stenehjem DD, Agarwal N. Comparative effectiveness of first-line VEGF TKI followed by second-line therapy with either a VEGF TKI or an mTOR in patients with metastatic renal cell carcinoma. Poster Presentation. 2015 Genitourinary Cancers Symposium. February 26-28, 2015. Orlando, FL. J Clin Oncol 33, 2015 (suppl 7; abstr 495).
  284. Merriman J, Parikh K, Tantravahi SK, Straubhar AM, Agarwal A, Sendilnathan A, Van Atta J, Batten J, Grossmann K, Samlowski W, Stenehjem D, Agarwal N. Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). Poster Presentation. 2014 ASCO Annual Meeting May 30–June 3, 2014, Chicago, IL. J Clin Oncol 32:5s, 2014 (suppl; abstr 4577)
  285. Bailey E, Tantravahi SK, Poole A, Wells C, Batten J, Merriman J, Stenehjem D, Agarwal N. Association of hand-foot syndrome (HFS), treatment dose reductions (TDRs), and outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL. J Clin Oncol 32:5s, 2014 (suppl; abstr 4580)
  286. Agarwal N, Tangen C, Hussain M, Lara Jr P, Higano C, Vaena D, MacVicar G, Li H, Crispino T, Quinn D, Vogelzang N, Thompson Jr I. SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) + TAK-700 with ADT + bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer (HSPC) (NCT01809691). Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS5102)
  287. Yu E, Tangen C, Higano C, Agarwal N, Pal SK, Alva AS, Heath E, Tat Lam E, Gupta S, Lilly M, Inoue Y, Chi K, Vogelzang N, Quinn D, Li H, Cheng H, Plymate S, Hussain M, Thompson Jr I. SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. Oral Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL. J Clin Oncol 32:5s, 2014 (suppl; abstr 5006)
  288. Cheng H, Li H, Higano C, Tangen C, Agarwal N, Yan J, Vogelzang N, Hussain M, Thompson Jr I, Tewari M, Yu E. Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer. Poster discussion session. 2014 ASCO Annual Meeting May 30-June 3, 2014, Chicago, IL J Clin Oncol 32:5s, 2014 (suppl; abstr 5017)
  289. Galsky M, Harshman L, Crabb S, Wong YN, Yu E, Chowdhury S, Powles T, Pal SK, Moshier E, Ladoire S, Hussain S, Agarwal N, Vaishampayan U, Recine F, Berthold D, Necchi A, Theodore C, Milowsky M, Bellmunt J, Rosenberg J. Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). Poster discussion session. 2014 ASCO Annual Meeting May 30-June 3, 2014 Chicago, IL J Clin Oncol 32:5s, 2014 (suppl; abstr 4512)
  290. Albiges L, Xie W, Lee JL, Rini B, Srinivas S, Bjarnason G, Ernst S, Wood L, Vaishamayan U, Rha SH, Agarwal N, Yuasa T, Pal SK, Koutsoukos K, Fay AP, Preston M, Cho E, Chin Heng DY, Choueiri T. The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell cancer database consortium. Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014 Chicago, IL J Clin Oncol 32:5s, 2014 (suppl; abstr 4576)
  291. Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, De Wit R, De Bono JS, Cruz F, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak P, Lee C, Tejura B, Borgstein NG, Dreicer R. Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel. Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014 Chicago, IL J Clin Oncol 32:5s, 2014 (suppl; abstr 5042)
  292. Diamond JR, Agarwal N, Bowles D, Lam ET, Werner T, Wu B, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S. Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib (AMG 386) and paclitaxel (PTX) in patients (pts) with advanced solid tumors. Poster Presentation. 2014 ASCO Annual Meeting May 30-June 3, 2014 Chicago, IL J Clin Oncol 32:5s, 2014 (suppl; abstr 2584)
  293. Tantravahi SK, Stenehjem DD,  Agarwal A, Kollepara SL, Batten JA, Ward M, Albertson D,  Wang JF, Liu T, Agarwal N. Clinical outcomes and survival of patients (pts) with sarcomatoid metastatic renal cell carcinoma (smRCC). Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. J Clin Oncol 32, 2014 (suppl 4; abstr 535)
  294. Parikh K,  Stenehjem DD, Sendilnathan A, Crispin H, VanAtta J, Batten JA, Sagesser D, Grossmann K, Samlowski W, Tantravahi SK, Agarwal N. Conditional survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD-IL2). Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. J Clin Oncol 32, 2014 (suppl 4; abstr 460)
  295. Batten JA, Samlowski W, Parikh K, Sendilnathan A, Van Atta J, Batten JA, Sagesser D, Grossmann K, Tantravahi SK, Stenehjem DD, Agarwal N. The association between rigors and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2) Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. J Clin Oncol 32, 2014 (suppl 4; abstr 487)
  296. Agarwal N, Parikh K, Tantravahi SK, Crispin H, VanAtta J, Batten JA, Sagesser D, Grossmann K, Samlowski W, Stenehjem DD. Clinical benefit (CB) of high dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC). Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. J Clin Oncol 32, 2014 (suppl 4; abstr 461)
  297. Stenehjem DD, Parikh K, Batten JA, VanAtta J, Crispin H , Sagesser D, Grossmann K, Tantravahi SK, Samlowski W, Agarwal N. Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2). Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. J Clin Oncol 32, 2014 (suppl 4; abstr 476)
  298. Cheng HH, Nadal R, Gulati R, Azad A, Twardowski P, Vaishampayan U, Agarwal N, Heath E, Pal SK, Rehman H, Leiter A, Batten J, Montgomery RB, Galsky MD, Chi KN, Antonarakis ES, Yu EY. The Effect of Prior Abiraterone (Abi) Use on the Efficacy of Enzalutamide (Enza) in Men with mCRPC. Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. J Clin Oncol 32, 2014 (suppl 4; abstr 18)
  299. Tsao CK, Agarwal N, Apolo AB, Lee KM, Godbold JH, Oh WK, Galsky MD. Phase Ib/II trial of gemcitabine, cisplatin, plus lenalidomide as first-line therapy for patients with metastatic urothelial carcinoma. Poster Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. J Clin Oncol 32, 2014 (suppl 4; abstr 321)
  300. Heng DY, Rini BI, Beuselinck B, Lee JL, Knox JJ,  Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Kanesvaran R, Choueiri TK. Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Oral Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. J Clin Oncol 32, 2014 (suppl 4; abstr 396)
  301. Ko JJ,  Xie W, Heng DY, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Harshman LC,  Pal SK,   Yuasa   T,   Smoragiewicz  M, Donskov  F,   Bamias   A,    Wood  L,  Ernst  DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK. The international metastatic renal cell carcinoma database consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT). Oral Presentation. 2014 Genitourinary Cancers Symposium. January 30-February 1, 2014, San Francisco, CA. J Clin Oncol 32, 2014 (suppl 4; abstr 398)
  302. Yick D , Heng C , Rini BI , Lee JL , Kroeger N , Srinivas S , Harshman LC , Knox JJ , BjarnasonGA , MacKenzie MJ , Wood L , Vaishampayan UN , Agarwal N , Pal SK , Tan MH , Rha SY , Yuasa T , Donskov F , Bamias A , North SA , Choueiri TK. First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC). Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting Chicago IL. May 31-Jun 4, 2013. J Clin Oncol 31, 2013 (suppl; abstr 4586)
  303. Sonpavde G , Pond GR , Agarwal N , Choueiri TK , Qu AQ , Fougeray R , Salhi Y , Vaughn DJ , James ND , Niegisch G , Albers P , Galsky MD , Wong YN , Stadler WM , O’Donnell PH , Vogelzang NH , Sridhar SS , Ko YJ , Sternberg CN , Bellmunt J. Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC). Poster Discussion. American Society of Clinical Oncology (ASCO) Annual Meeting Chicago IL. May 31-Jun 4, 2013. J Clin Oncol 31, 2013 (suppl; abstr 4524)
  304. Chittoria N , Zhu H , Choueiri TK , Kroeger N , Lee JL , Srinivas S , Knox J , Bjarnason BA , MacKenzie MK , Wood L , Vaishamayan UN , Agarwal N , Pal SK , Tan MH , Rha SY , Yuasa T , Donskov F , North SA , Rini BI , Yick D , Heng C. Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium. Poster Presentation. May 31-Jun 4, 2013. J Clin Oncol 31, 2013 (suppl; abstr 4565)
  305. Kroeger N , Lee JL , Bjarnason GA , Knox JJ , MacKenzie MJ , Vaishamayan UN , Wood L , Srinivas S , Rha SY , Pal SK , Yuasa T , Donskoy F , Agarwal N , Tan MH , Bamias A , Kollmannsberger CK , North SA , Rini BI , Choueiri TK , Yick D , Heng C. Treatment response and survival outcome of patients with late relapse (LR) from renal cell carcinoma (RCC) in the era of targeted therapy. Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting Chicago IL. May 31-Jun 4, 2013. J Clin Oncol 31, 2013 (suppl; abstr 4578)
  306. Agarwal N, Wade M, Batten J, Davidson C, Sun SL, Sharma S. Phase I Study of Histone Deacetylase Inhibitor Belinostat in Combination with Warfarin in Patients with Solid Tumors or Hematological Malignancies. Poster Presentation (Abstract: 1172): AACR annual meeting. Washington, DC, April, 8, 2013
  307. Cannon-Albright LA, Teerlink CC, Agarwal N. Identification of significant linkage evidence for lethal prostate cancer on chromosome arm 11p15. Poster Presentation (Abstract: 1341): AACR annual meeting. Washington, DC, April, 8, 2013.
  308. Zollinger L, Morton K, Agarwal N, Kadrmas D, Christian P, Beardmore B,  Butterfield  R, Hoffman J. 18F-FDG and FLT PET for early prediction of response to Sunitinib in metastatic renal cell carcinoma. Poster Presentation (abstract # 1605). Society of Nuclear Medicine & Molecular Imaging (SNMMI), 2013 60th Annual Meeting, Vancouver, BC, Canada June 8-12, 2013.
  309. Campo RA, O’Connor K, LaStayo P, Light KC, Agarwal N, & Kinney AY. Effects of a 12-week Qigong intervention on fatigue and global distress in senior prostate cancer survivors and their family members. Poster, 2013 American Psychosomatic Society Annual Meeting, Miami, FL, March 13-16, 2013.
  310. Campo RA, Light KC, O’Connor K, Nakamura Y, Lipschitz D, LaStayo P, Agarwal N, & Kinney AY. Physical activity and quality of life associations with telomere length among senior female cancer survivors enrolled in a Tai Chi Chih trial. Poster Presentation Society of Behavioral Medicine (SBM) Annual Meeting, San Francisco, CA. March 20, 2013.
  311. Campo RA, O’Connor K, LaStayo P, Light KC, Agarwal N, Kinney AY. Effects of a 12-week Qigong intervention on fatigue and global distress in senior prostate cancer survivors and their family members. Poster Presentation at the American Psychosomatic Society (APS) Annual Meeting. Miami, FL Mar 13, 2013
  312. Dahal A, Bellows BK, Sonpavde G, Galsky MD, Agarwal N. Cisplatin Associated Nephrotoxicity in Clinical Trials using Serum Creatinine (SCr) vs. Calculated Glomerular Filtration Rate (GFR) as Inclusion Criterion: a Meta-Analysis. Poster Presentation. 2013 Genitourinary Cancers Symposium. February 14-16, 2013, Orlando, FL. J Clin Oncol 31, 2013 (suppl 6; abstr 272)
  313. Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Fougeray R, Niegisch G, Wong YN, Sridhar SS, Sternberg CN, Sonpavde G. Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC). Poster Presentation. 2013 Genitourinary Cancers Symposium. February 14-16, 2013, Orlando, FL. J Clin Oncol 31, 2013 (suppl 6; abstr 301).
  314. Gartrell BA, Ying J, Sivendran S, Agarwal N, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: A systematic review and meta-analysis. Poster Presentation. 2013 Genitourinary Cancers Symposium. February 14-16, 2013, Orlando, FL. J Clin Oncol 31, 2013 (suppl 6; abstr 362)
  315. Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S,Vaishamayan UN, Rha SY, Pal SK, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DYC. Metastatic non clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the international metastatic renal cell carcinoma database consortium (IMDC) prognostic model to predict outcomes. Poster Presentation. 2013 Genitourinary Cancers Symposium. February 14-16, 2013, Orlando, FL. J Clin Oncol 31, 2013 (suppl 6; abstr 396).
  316. Sivendran S, Ying J, Gartrell B, Agarwal N, Boucher K, Choueiri T, Sonpavde G, Oh WK, Galsky MD. Metabolic complications with the use of mTOR inhibitors for cancer therapy: a systematic review and meta-analysis. Poster Presentation. 2013 Genitourinary Cancers Symposium. February 14-16, 2013, Orlando, FL. J Clin Oncol 31, 2013 (suppl 6; abstr 398).
  317. Kanth P, Stayner J, Grossman K, Agarwal N, Peterson K, Boynton K, Fang J, Valentine J, Bronner M, Burt R, Jewel Samadder N. Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody (Ipilimumab) Associated Enterocolitis. Poster Presentation (P861), American College of Gastroenterology (ACG), 77th Annual Meeting, October 19 – 24, 2012, Las Vegas, Nevada.
  318. Munster P, van der Noll R, Voest E, Specht J, Werner TL, Dees EC, Tan AR, Daud A, Schellens J, Lolkema MP, Griffin M, Agarwal N, Falchook GS, Kleha JF, Durante M, Smith DA, Adams L, Greshock J, Morris SR, Kurzrock R. PI3K kinase inhibitor GSK2126458 (GSK458): Clinical activity in select patient (pt) populations defined by predictive markers (Study P3K112826). European Society of Medical Oncology (ESMO) 2012 Congress, 28 September – 2 October, Vienna, Austria. Oral Presentation (abstract ID:1500).
  319. Kinney A, Birmingham W, Kohlmann W, Agarwal N. Patients and providers cognitions regarding genomic risk assessments for prostate cancer susceptibility and cancer prevention. (Code: 12EHP- 0250). Oral Presentation. 26th European Health Psychology Society (EHPS) Conference, Prague, Czech Republic, August 21st -25th, 2012.
  320. Maughan B, Boucher KM, Agarwal N, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko Y, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Beer TM, Sternberg CN, Rosenberg JE, Bellmunt J, Sonpavde G. Progression-free survival at 6 months (PFS6) as an endpoint in trials of second-line therapy for advanced urothelial carcinoma (UC). Poster Discussion Session. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5, 2012. [J Clin Oncol 30, 2012 (suppl; abstr 4525)].
  321. Grivas P, Agarwal N, Levine E, Mcvicar G, Puzanov I, Siefker-Radtke A, Srinivas S, Twardowski P, Eisenberger M, Quinn D, Yu E, Vaishampayan U, Hussain M. Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC). Oral Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5, 2012. [J Clin Oncol 30, 2012 (suppl; abstr 4506)]
  322. Carles J, Fizazi K, Weems G, Chance L, Agarwal N. Results of a phase 2 study of pralatrexate in patients with advanced or metastatic relapsed transitional cell carcinoma (TCC) of the urinary bladder. Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5, 2012. [J Clin Oncol 30, 2012 (suppl; abstr 4574)].
  323. Vogelzang N, Ely B,  Fink LM, Goldkorn A, Tangen CM, Twardowski PM, Van Veldhuizen PJ, Agarwal N, Carducci M, Monk JP, Garzotto MG, Mack PC, Lara PN, Higano CS, Hussain MH, Quinn DI, Cote RJ, Thompson IM. Results of Circulating Tumor Cell Counts Using the CellSearch Platform in a Prospective Randomized Phase III SWOG-Sponsored Prostate Cancer Trial (S0421) Oral Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5, 2012.[J Clin Oncol 30, 2012 (suppl; abstr 10503)].
  324. Quinn DI, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Carducci M, Monk PJ, Twardowski PW, Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang N, Thompson IM. SWOG S0421:  Phase III study of Docetaxel (D) and Atrasentan (A) versus Docetaxel and Placebo (P)  for  Men  with  Advanced  Castrate  Resistant  Prostate  Cancer  (CRPC). Oral Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5, 2012.[ J Clin Oncol 30, 2012 (suppl; abstr 4511)].
  325. Goldkorn A, Ely B,  Quinn DI, Tangen CM, Tai YC, Twardowski PW, Lara PN, Van Veldhuizen PJ, Agarwal N, Carducci M, Monk PJ, Garzotto MG, Mack PC, Higano CS, Hussain MHA, Vogelzang NJ, Cote RJ, Thompson IM. Results of Telomerase Activity Measurements from Live Circulating Tumor Cells Captured on a Slot Microfilter in a Phase III SWOG-coordinated Prostate Cancer Trial (S0421) Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5, 2012. [J Clin Oncol 30, 2012 (suppl; abstr 4663)].
  326. Xie WL, Choueiri TK, Lee J, Harshman LC, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Vaishampayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, and Heng DYC. Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma (mRCC) treated with targeted therapy: results from the International mRCC Database Consortium. Poster Discussion. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5, 2012. [J Clin Oncol 30, 2012 (suppl; abstr 4538)].
  327. Heng, DYC, Xie WL, Choueiri TK, Lee J, Harshman LC, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Vaishampayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, and Choueiri TK. An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials. Poster Discussion. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 1-5, 2012. [J Clin Oncol 30, 2012 (suppl; abstr 4536)].
  328. Agarwal N, Boucher KM, Maughan B, Hussain SA, Kaufman DS, LorussoV, Moore MJ, Galsky MD, Sonpavde G. Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. (Abstract #308). Poster Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA. [J Clin Oncol 30, 2012 (suppl 5; abstr 308)].
  329. Heng DYC, Lee JL, Harshman LC, Bjarnason G, Razak AR, MacKenzie MJ, Wood L Vaishampayan UL, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North, S, Rini BI, Choueiri TK, International mRCC Database Consortium. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). (Abstract #387). Poster Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA. [J Clin Oncol 30, 2012 (suppl 5; abstr 387)].
  330. Heng DYC, ChoueiriTK, Lee JL, Harshman LC, Bjarnason G, Knox JJ, MacKenzie MJ, Vaishampayan UL, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North, S,A, Rini BI, Wood L, International mRCC Database Consortium. A multicentered population based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility  criteria  for  clinical  trials.  (Abstract  #353).  Oral  Presentation.  2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA. J Clin Oncol 30, 2012 (suppl 5; abstr 353)
  331. Choueiri TK, Xie WJL, Harshman LC, Bjarnason G, Knox JJ, MacKenzie MJ, Wood L, Vaishampayan UL, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North SA, Rini BI, Heng DYC. Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) targeted therapy (TT): Results from  the  international  mRCC  database  consortium. (Abstract #358). Poster Presentation. 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco, CA. [J Clin Oncol 30, 2012 (suppl 5; abstr 358)].
  332. Sharma S, Voest E, Hagner N, Witteveen PO, Lolkema M, Agarwal N, Valera S, Li J, Mires D, Porro MG, Woo MM, and Hess D. Effects of Renal Function on the Pharmacokinetics of panobinostat in Patients with Advanced Cancer: A Phase I Study. Publication only. Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 5001.
  333. Hess D, Hagner N, Clive S, Gelderblom H, Rossmann E, Agarwal N, Grazia Porro M, Hengelage T, St-Pierre A, Gazi L, Li J, Woo MM, and Sharma S. Effects of Hepatic Function on the Pharmacokinetics and Safety of Panobinostat in Patients with Advanced Cancer: A Phase I Study. Publication only. Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 5007.
  334. Cannon Albright LA, Teerlink C, Agarwal N, Stephenson R. Evidence for a strong genetic contribution to lethal prostate cancer (Abstract-1205W). Poster Presentation. International Congress of Human Genetics / American Society of Human Genetics. October 11-15, 2011. Montreal, Quebec, Canada.
  335. Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason GA, Wood L, Vaishampayan UL, MacKenzie MJ, Knox JJ, Agarwal N, Kollmannsberger CK, Tan MH, Rha SY, Donskov F, North S, Choueiri TK, Heng DYC. The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts). Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7, 2011. [J Clin Oncol 29: 2011 (suppl; abstr 4555)]
  336. Fury MG, Sherman EJ, Lisa DM, Agarwal N, Algazy KM, Brockstein B, Langer CJ, Lim D, Mehra R, Rajan SK, Jafri N, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng KK, Xiao H, Haque S, Pfister DG. A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m2 for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7, 2011. [J Clin Oncol 29: 2011 (suppl; abstr 5563)]
  337. Agarwal N, Sahu M, Abhyankar DJ, Werner TL, Benjamin B, Srinivas R, Sharma S. A drug-drug interaction study of everolimus (a mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF 2, PDGF and EphB4 receptors, in patients with advanced urologic tumors. Publication only. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7, 2011. [J Clin Oncol 29: 2011 (suppl; abstr e15077)]
  338. Lam ET, Wong MKK, Agarwal N, Redman BG, Logan T, Flaig TW, Monk III JP, Jarkowski A, Sendilnathan A, Bolden M, Kuzel T, Olencki T. Safety and efficacy of sequencing high-dose interleukin 2 (IL2) after tyrosine kinase inhibitor (TKI) therapy for metastatic renal cell carcinoma. Publication only. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3-7, 2011.[J Clin Oncol 29: 2011 (suppl; abstr e15079)]
  339. Kinney AY, Campo R, Agarwal N, Connor KO, Boucher K, Pappas L, LaStayo P, Nakamura Y, Irwin MM, Light K. Feasibility and acceptability of a randomized trial of Tai Chi Chih in senior female cancer survivors. Poster Presentation. International Psycho-Oncology Society (IPOS) 13th World Congress of Psycho-Oncology, Antalya, Turkey, October 16-20, 2011.
  340. Kinney AY, Campo R, Connor KO, Boucher K,  Pappas L, LaStayo P, Nakamura Y, Irwin MM, Agarwal N, Light K. Randomized Trial of Tai Chi Chih in Elderly Breast Cancer Survivors on Quality of Life and Physical Functioning: Interim Outcomes. Poster Presentation. MASCC is Multinational Association of Supportive Care in Cancer (MASCC) 2011 International Symposium, Athens, Greece, June 23-25, 2011.
  341. Grossmann KF, Blankenship MB, Akerley W, Terrazas MC, Kosak KM, Boucher KM, Buys SS, Jones K, Werner TL, Agarwal N, Weis J, Sharma S, Ward JH, Shami PJ. A phase I clinical study investigating disulfiram and copper gluconate in patients with advanced treatment-refractory solid tumors involving the liver. Poster (abstract 1308). American Association of Cancer Research (AACR) 102nd Annual Meeting, Orlando, Florida, April 2 – 6, 2011.
  342. Alva AS, Agarwal N, Siefker-Radtke AO, Roth BJ, Smith DC, Daignault S, Srinivas S, Bradley DA, Hussain M. Targeting epidermal growth factor receptor (EGFR) in urothelial cancer (UC): A phase II randomized trial of cisplatin (C) with gemcitabine (G) with or without cetuximab. Poster Presentation. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 4-8, 2010. [J Clin Oncol 28:7s, 2010 (suppl; abstr TPS239)]
  343. Graves KK (presenter), Reid J, Nord John, Haslem DS, Agarwal N. “EDTA-dependent pseudothrombocytopenia: a laboratory artifact with potentially serious consequences”. Poster Presentation. American College of Physicians (ACP) Annual Meeting, Philadelphia, PA, April 23- 25, 2009.
  344. Reid J (presenter), Graves KK, Haslem DS, Agarwal N. “Bleeding due to Factor XIII deficiency is associated with normal screening coagulation tests.” Poster Presentation. American College of Physicians (ACP) Annual Meeting, Philadelphia, PA. April 23-25, 2009.
  345. Agarwal N (presenter), Swierczek S, Lorenzo FR, Naidoo K, Agarwal AM, Nussenzveig RH, Whisenant J, Coetzer TL, Prchal JT. Novel exon 2 alpha spectrin mutation in a Caucasian family with pyropoikilocytosis, elliptocytosis, and normal morphology: three phenotypes due to decreased spectrin mRNA and intragenic crossover. Poster Presentation. American Society of Hematology (ASH) Annual Meeting, San Francisco, CA, December 2008. [Blood 2008; 112: Abstract 3840].
  346. Agarwal N (presenter), Swierczek S, Nussenzveig RH, Samuelson S, Parker CJ, Prchal JT. Validation of a novel clonality assay in patients with clonal hematologic disorders. Poster Presentation. American Society of Hematology (ASH) Annual Meeting, San Francisco, CA, December 2008. [ Blood 2008; 112: Abstract 3718].
  347. Agarwal AM (presenter), Agarwal N, Glenn M, Lim H. Spontaneous splenic rupture complicating primaryt treatment refractory Burkitt lymphoma. Poster Presentation. College of American Pathologists (CAP) annual meeting, San Diego, CA, September 2008. [ Archives of Pathology & Laboratory Medicine, 2008; 132: 1454–1527].
  348. Nussenzveig R (presenter),  Swierczek  S,  Agarwal  N,  Prchal  J.  Hematopoiesis  is  Not  Clonal in Healthy Elderly Females? Poster Presentation. Stem Cells, Cancer and Aging. Keystone Symposia. Singapore. 29 September – 3 October 2008. [Stem cells, Cancer and Aging 2008; 77: abstract 250].
  349. Agarwal N (presenter), Swierczek S, Rothstein G, Nussenzveig R, Prchal J. Hematopoiesis is Not Clonal in Healthy Elderly Females? Poster Presentation. International Society of Experimental Hematology Annual Meeting. Boston, MA. July 2008. [Experimental Hematology 2008; 36 (7), Supplement 1:P127].
  350. Agarwal N (presenter), Swierczek S, Rothstein G, Nussenzveig R, Prchal J. Is Hematopoiesis Clonal in Healthy Elderly Females? Poster Presentation. American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, December 2007. [Blood. 2007; 110 (11): abstract 2243].
  351. Agarwal N (presenter), Kutlar F, Reading S, Kutlar A, Prchal J. Missense Mutation of the Last Nucleotide of Exon 1 of beta-globin Gene Interferes with the Expression of Wild Allele. Poster Presentation. American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, December 2007. [Blood. 2007; 110 (11): abstract 1777].
  352. Agarwal N(presenter), Swierczek S, Naidoo K, Prchal JT, Coetzer TL. A Novel Mutation of the Spectrin Gene in a Family of Northern European Descent is Associated with Three Different Phenotypes. Poster Presentation. American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, December 2007. [Blood. 2007; 110 (11): abstract 1717].
  353. Agarwal N(presenter), Mojica-Henshaw MP, Kutlar F, Gaikwad A, Ou CN, Kutlar A, Prchal JT. Novel Mechanism of β0 Thalassemia: Missense Mutation of the Last Nucleotide of β Globin Exon 1 (G->C) not only Leads to Undetectable Transcript but interferes with the Expression of Wild Type Allele. Oral Presentation, 9th Annual Mayo Clinic Hematology/Oncology Fellow’s Research Symposium, Amelia Island, Florida, August, 2007. [This was an oral presentation. This meeting does not publish any proceedings of the meeting.
  354. Agarwal AM(presenter), Agarwal N, Tryka AF, Ward JH, Lim MS. Blastic Transformation of Follicular lymphoma. Poster Presentation. College of American Pathologists (CAP) annual meeting, Chicago, Illinois, September 2007. [Archives of Pathology & Laboratory Medicine, 2007; 131:1406–1480].
  355. Agarwal N (presenter), Mojica-Henshaw MP, Kutlar F, Gaikwad A, Ou CN, Kutlar A, Prchal JT. Novel Mechanism of β0 Thalassemia: Missense Mutation of the Last Nucleotide of β Globin Exon 1 (G->C) Leads to Undetectable Transcript and Mutant Peptide. Poster Presentation. American Society of Hematology (ASH) Annual Meeting, Orlando, FL, December 2006. [Blood, 2006; 108: A1598].
  356. Spahr JE, Agarwal N, Rodgers GM. Treatment of Immune-Mediated Thrombocytopenia Purpura with Concurrent IVIg and Platelet Transfusion: A Retrospective Review of 40 Patients. Publication Only. American Society of Hematology (ASH) Annual Meeting, Orlando, FL, December 2006. [Blood, 2006; 108: A 3972].
  357. Wada DA(presenter), Agarwal N, Florell SR, Lim MS. “Recurrent squamous cell carcinoma and follicular lymphoma arising in the scalp two years after treatment for lymphoma”. Poster Presentation. College of American Pathologist (CAP) Annual Meeting, San Diego, CA, September 2006. [Archives of Pathology and Laboratory Medicine. 2006; 130: 1362–1403 (P14)].
  358. Agarwal N (presenter), Kirby P, White ML, Jogerst GJ, Grabowski TJ. A Rapidly Progressive Case of Sporadic Progressive Sub cortical Gliosis (PSG). Poster Presentation. Annual Dementia Congress, Washington DC, September 2003.
  359. Agarwal N (presenter), Klix M, Burns CP. “Monoclonal Gammopathy of Undetermined Significance (MGUS) presenting as Acquired von Willebrand Disease”. Oral Presentation.  American College of Physician (ACP) Annual Meeting, San Diego, April 2003.
  360. Agarwal N (presenter), Ippolito L, Mitros FA, Goeken J, Schimdt WN, Voigt MD, LaBrecque DR. Clinical significance of atypical p-ANCA and ANA in autoimmune hepatitis. Poster Presentation. American College of Physicians Annual Meeting, San Diego, April 2003.
Follow me on Twitter
%d bloggers like this: